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ABSTRACT 
Hamsa Lakshmi Subramaniam: The Effect of Antiretroviral Therapy on Preterm Birth in a U.S 
Population of Women Living With HIV: A Reexamination of Analysis Methods 
(Under the direction of Audrey Pettifor)  
Harmful effects of combination antiretroviral therapy (cART) in pregnancy is a research 
priority given its widespread use in preventing vertical transmission of HIV. Studies 
investigating the relationship between ART and preterm birth (PTB) offer conflicting results as 
to whether PI cART is harmful in causing PTB, likely due to methodological challenges and not 
truly harmful effects. Our study reexamines methods used in the literature with the Women and 
Infants Transmission Study data (WITS). WITS is a US-based observational cohort designed to 
study the natural course of maternal-infant HIV-1 infection between 1990 and 2005. Exposure 
categories considered for both aims are no therapy, Zidovudine (ZDV) monotherapy; PI-based 
cART and non-nucleoside reverse transcriptase inhibitor (NNRTI) cART. For Aim 1, we used 
the complement of the Kaplan-Meier estimator and inverse probability weights to estimate PTB 
risk by time-varying exposure. A total of 1,067 HIV-positive pregnancies in 932 women were 
followed until delivery.  The weighted risk differences indicated PI cART was harmful compared 
to NNRTI cART in preventing PTB, though insignificant. Exposure to either combination 
therapy were significantly associated in preventing very preterm compared to other exposures.  
For Aim 2, we demonstrated target trial emulation to examine the intention-to-treat effect of 
exposure on PTB. Women were enrolled and assigned treatment between 18 and 22 weeks to 
emulate trial enrollment at 20 weeks. We assumed that exposure assignment was conditional on 
measured baseline covariates to emulate baseline randomization. Log-Poisson models with 
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robust variance estimators were used to report risk and risk ratios with 95% confidence intervals. 
Two hundred and six women were assigned their enrollment exposure. After adjusting for 
baseline covariates, women starting PI cART at 20 weeks had increased risk of PTB when 
compared to all other exposures, though all effect estimates were statistically insignificant. This 
finding is contrary to what is established in the ART literature. Although the WITS was not the 
ideal candidate for demonstrating the use of survival analysis or target trial emulation, both 
methods can accommodate the realities of observational cohort data and should be considered as 
an alternative to conventional binary methods.  
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CHAPTER 1: SPECIFIC AIMS 
An increasing number of HIV-infected women of reproductive age are initiating 
antiretroviral therapy worldwide. Because of this, the number of women on treatment before and 
during pregnancy is increasing. Modern HIV treatments, known as highly active antiretroviral 
therapy (HAART), effectively prevent vertical transmission from mother to child, contributing to 
a growing population of individuals living without HIV, due to in-utero exposure to antiretroviral 
drugs. Current research priorities have turned to the effect of treatment initiation timing and 
length of exposure to certain classes and combinations of antiretroviral drugs that could be 
associated with preterm birth and other adverse birth outcomes. This study analyzed data from 
the Women’s Infant Transmission Study (WITS), to further refine our understanding of the 
possible effect of HIV treatment type on preterm birth (delivery prior to 37 weeks gestation) 
using revised methodological approaches than those used in the literature.  
The WITS cohort is a large, multi-site study of HIV-positive women in pregnancy and 
their infants collected in the United States from 1988 to 2005, with follow-up ending in 2008.  
While related questions have been explored using these data in the past, this study proposes a re-
analysis of the WITS data for the following reasons:  
1. The published analysis of preterm birth outcomes includes women in the cohort 
enrolled between 1990 and 2002, however enrollment continued until 2005.3 The proposed 
analysis would consider an additional 600 women enrolled between 2002 and 2005.  
2. Analyses examining the relationship between preterm birth and HIV treatment are 
subject to a range of methodological flaws. Perhaps the most common of these are erroneously 
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adjusting for prior preterm birth and inappropriately utilizing binary methods in the context of 
longitudinally collected observational data.   Binary regression methods do not easily 
accommodate time-varying exposure, competing risks or censoring, which are common features 
of pregnancy cohorts. Reanalyzing to estimate preterm birth risk utilizing survival methods or 
appropriately using binary methods to estimate easily interpretable measures of effect would be 
more appropriate given the presence of late-entry and time-varying exposure to HIV treatment as 
well as to facilitate public health action. 
To explore the use of alternative epidemiology methods to understand the effect of in-
utero exposure to PI-based ART on preterm birth, this dissertation has two aims.  
Aim 1: Estimate the effect of ART regimen on risk of preterm birth among HIV-infected 
pregnant women enrolling after 1996 who initiate treatment after conception and prior to 28 
weeks gestation using survival methods. We hypothesize that the effect of PI ART on preterm 
birth will not be different than that among pregnancies exposed to other combination therapies.   
Aim 2: Estimate the causal effect of ART regimen initiated at 20 weeks gestation on risk 
of preterm birth among HIV-infected pregnant women by emulating a target trial using 
observational data. We hypothesize that the effect of PI ART on preterm birth derived from the 
emulated target trial will not be different than that among pregnancies exposed to other 
combination therapies, but will be protective compared to monotherapy and no therapy.  
  
3 
CHAPTER 2: BACKGROUND 
2.1 HIV and Pregnancy in the United States 
The public health burden of HIV remains high worldwide, particularly among 
reproductive-aged women of color. Of the 34.5 million adults living with HIV globally in 2016, 
nearly half of the population were women between 16 and 45 years old.4 In that same year, adult 
and adolescent women comprised approximately 20% of all new HIV diagnoses.5,6  In the United 
States, HIV incidence among adults has declined overall since treatment and prevention efforts 
gained momentum starting in the early 1990s.  Even so, HIV incidence among Black women of 
reproductive age is 20 times higher compared to white women -  a difference that has not 
meaningfully changed from the mid-1980s when HIV was first discovered among women in the 
United States.6–8 As of 2017, 69% of new HIV cases were Black or Latino, and 19% of new 
cases were women of reproductive age.9 As a result, women of color are more likely than all 
other racial groups combined to conceive and give birth while living with HIV.  
Pregnant women are a special population within those living with HIV due to the 
additional risk of transmitting HIV to their infant. The estimated number of women living with 
HIV who give birth in the United States has increased by 30% between 2000 and 2017.10 
Transmission of HIV to an infant is most likely to occur during the intrapartum and post-partum 
periods. During the intrapartum period marked by labor and delivery, significant mixing of 
maternal and fetal blood and fluids occurs, exposing the fetus to infection.  Post-partum 
transmission of HIV occurs when a woman passes HIV to her child via breastmilk containing the 
virus.11  Without any ART, an estimated 15-30% of babies born to HIV-positive mothers will 
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acquire HIV in-utero12,13 or in the intrapartum period, and an additional 5-40% will be infected 
through breastfeeding. 11,14,15  
Health outcomes for pregnant women living with HIV and their children have improved 
with the introduction of new drugs and interventions since the early 1990s.  HIV-testing for 
pregnant women; HIV treatment provision during pregnancy, delivery and post-partum periods; 
avoidance of breastfeeding, and elective cesarean section dramatically reduced rates of vertical 
transmission in the United States from 43.1 per 100,000 births in 1992 to 1.8 per 100,000 births 
in 2013.16,17 Until 2000, women and clinicians generally decided on an ad hoc basis whether C-
section was appropriate given the overall pregnancy context. If a woman was severely infected 
with HIV, indicated by a high viral load in her blood, a C-section delivery would avoid the 
mixing of infected maternal fetal blood during spontaneous vaginal labor, thereby minimizing 
infant risk of exposure to HIV.18  Similarly, early guidelines advised exclusive formula-feeding 
to prevent infant exposure to infected breastmilk altogether. Since 2012 however, advances in 
HIV treatment type, availability and adherence, coupled with improved obstetric care have 
allowed HIV-positive pregnant women to experience pregnancy, delivery, breastfeeding and 
post-partum periods normally provided they are able to achieve viral suppression.4,19  
2.2 HIV Treatment in Pregnancy 
The most significant of these interventions in preventing vertical HIV transmission 
widespread HIV testing and initiating women on ART during pregnancy. The first Centers for 
Disease Control (CDC) recommendations on preventing mother-to-child transmission in 1987 
recommended that women delay pregnancy and avoid breastfeeding until more is known about 
the risks of transmission.20 The first HIV antiretroviral therapy discovered was a nucleoside 
reverse transcriptase inhibitor (NRTI) called azidothymidine (AZT), approved by the Federal 
Drug Administration (FDA) 1987.  AZT was later renamed zidovudine (ZDV) and was shown to 
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be effective for 98% of non-pregnant adults through 24 weeks of treatment, however the 
beneficial effects declined shortly after.21 Even so, the United States Public Health Service 
recommended antenatal oral administration of ZDV for pregnant women, beginning at 14-34 
weeks and continuing throughout pregnancy to prevent vertical transmission.18 It was further 
recommended that women receive intrapartum intravenous ZDV to suppress viral load during 
delivery, followed by postnatal oral administration of ZDV to the infant for six weeks after 
delivery.22 The use of this three-part regimen of ZDV monotherapy rapidly became standard 
practice. Consequently, vertical transmission risk was reduced by 67.5% in women with CD4 
cell counts > 200 cells/mm.22,23 
Additional NRTIs were developed and put on the market, however all of them faced 
similar challenges as ZDV when administered alone.24 When HIV’s highly mutagenic properties 
were discovered, treatment with one drug caused resistance and eventual inefficacy of treatment. 
Given the limitations of ZDV monotherapy, the research and clinical communities hypothesized 
about the possible benefits of treating HIV with more than one drug simultaneously, however 
more drug development was necessary to test this hypothesis.  After the introduction of ZDV in 
1987, the next drug to market in 1995 was Saquinavir (SQV), a PI.24 Shortly thereafter, 
Nevirapine (NVP), the first of the non-nucleoside reverse transcriptase inhibitors (NNRTI), was 
approved.24 HIV medications and the year of FDA approval are detailed in Table 2.1.  
The discovery of combination therapies known as HAART (referred to as combination 
ART, cART in subsequent chapters) in 1996 led to substantially better survival and immune 
recovery than prior treatment regimens. Despite the development of new classes of drugs, mono- 
and dual- therapy still did not offer sustained viral suppression and immune recovery.24,25 Trials 
confirmed that combinations with three drugs led to durable viral suppression and continues to 
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be the standard of care in 2020.26  After the discovery of HAART in 1996, HIV-positive adults 
meeting the recommended CD4 thresholds were advised to initiate or switch to HAART (Table 
2.2). Pregnancy treatment guidelines extended from the adult guidelines with modifications, 
usually based on possible side-effects for the woman or toxicities for the child.27  A considerable 
amount of evidence demonstrated that early initiation to treatment increased likelihood of 
morbidity-free survival and reduction in HIV transmission. In March of 2012, HIV guidelines 
recommended universal “test and treat”, removing all CD4 eligibility thresholds and encouraging 
clinicians to initiate treatment upon a HIV diagnosis.4,28 As a result, perinatal transmission rates 
in the United States dropped from 42.8 per 100,000 live births in 1991, to 1.3 per 100,000 live 
births in 2017. 29,30   
With the science of mother-to-child HIV prevention now largely established and the 
worldwide incidence of pediatric HIV on the decline, attention has turned to adverse effects of 
type and timing ART exposure in pregnancy.31 Preterm birth is a primary cause for a host of 
short and long-term developmental challenges faced by children.32 If there is indeed a significant 
association between ART and preterm birth, exploring alternative HIV treatment regimens may 
prevent adverse birth outcomes for the 270,000 HIV-positive women of reproductive age and 
their children in the United States alone.9  
2.3 ART and Preterm Birth 
The etiology of preterm birth is the principle unsolved problem in perinatal medicine. 
Preterm birth accounts for 75% of perinatal mortality worldwide, and more than half of long-
term morbidity of children, including cognitive disability, poor motors skills, behavioral 
problems, hearing loss, and chronic lung disease.33–36 HIV is known to be associated with 
preterm birth. Prior to the scale-up of HIV treatment in the United States, approximately 35% of 
HIV-exposed babies were born preterm, compared to 10% among HIV-negative women. 36,37 
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Women living with HIV share other risk factors for preterm birth, like gestational diabetes and 
gestational hypertension; 3,38 excessive alcohol and drug use;34,36 and smoking cigarettes both 
prior to and during pregnancy.37 It is clear that the causes of preterm birth are complex, 
particularly among HIV-positive women.  
A growing literature suggests that certain types of ART could cause preterm birth. In 
1998, a Swiss group reported an increased risk of preterm birth among women receiving 
HAART in pregnancy.41 Since then, a multitude of studies examining the relationship between 
ART and adverse birth outcomes have emerged from all over the world, using surveillance, 
observational and trial data.35,36,42,43 Risks have been suggested both by regimen type, and timing 
of HIV initiation as it relates to conception. The protease inhibitor class of drugs has been 
commonly implicated in causing preterm birth, both in high- and low- income contexts.44–46 
Additionally, preconceptional ART initiation has been suggested to cause preterm birth 
compared to women initiating ART during pregnancy.47–50  
The suggestion that preconceptional exposure to HIV treatment causes preterm birth is 
“at odds with biology.”51  Findings from the PROMISE trial conducted in several sites sub-
Saharan Africa report that women who initiated any ART combination preconceptionally were 
more likely to experience preterm birth compared to women who initiate ART during 
pregnancy.47,48 Similar results were found in studies conducted in Botswana49 and Ireland.50 
Extending these findings, longer duration of ART exposure with initiation prior to pregnancy 
have shown the highest rates of preterm birth.48,52,53  Preterm birth occurs as a result of premature 
initiation of the labor cascade, marked by acute inflammation. Any untreated infection causes 
immune activation and systemic inflammation. Controlling HIV infection through ART will 
minimize the inflammatory response, thereby lowering preterm birth risk. Use of ART prior to 
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conception would therefore reduce, and not increase, the risk of preterm birth.54,55  Even so, it is 
possible that certain ART classes – while preventing transmission of HIV - contain inflammatory 
agents that could cause premature initiation of the labor cascade.38 If treatment for HIV is in fact 
causing premature delivery in addition to the infection, further study is of urgent importance 
considering the risks of lifetime disability and death of the child.   
Even so, these conclusions could be subject to systematic selection bias making it seem 
that risk of preterm birth is higher among preconceptional ART users, when in reality, there is no 
such risk.51,56 While HIV treatment exposure later in pregnancy could be associated with 
iatrogenic preterm birth, a study from Spain found that early exposure is not associated with 
spontaneous preterm birth at all.57 Perhaps most convincing is that treating HIV infection as 
early as possible will always be better than the alternative because sustained HIV infection is 
known to not only cause HIV transmission, but also to be strongly associated with preterm 
birth.54,55  Further comparative evaluations of treatment regimens utilizing appropriate analysis 
methods are needed. 
2.4 Limitations in the Current Research 
Studies exploring the effect of ART type and timing of exposure on preterm birth are 
limited in three primary ways. First, studies can be prone to systematic selection bias. Timing of 
ART initiation with respect to gestational age is commonly reported as a risk factor for preterm 
birth. Several observational studies conducted in Europe, the United States, and sub-Saharan 
Africa have reported that preconceptional ART is associated with increased risk or odds of 
preterm birth.43,49,58–61 As mentioned previously, this finding is inconsistent with biological 
plausibility and is likely due to the systematic exclusion of women who initiate ART late in 
pregnancy or after delivery.51,56  Women initiating ART after delivery are often removed from 
the risk set (even if they experienced preterm birth) due to poorly defined inclusion criteria 
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conditioning on exposure early in gestation. This makes it appear that those continuing on 
preconceptional ART have a higher risk of preterm birth in comparison.51 One way to address 
this type of bias is to include all fetuses at risk of the outcome – independent of initiation timing 
– in estimating risk.62  By extension, cohort membership is defined by current exposure, however 
observational analyses of extant data often inadvertently violate this principle by using “future 
exposures” to define present, analytic cohort membership inducing both selection bias and 
possibly immortal person-time.63 
Second, inferences can be limited by the use of inappropriate analysis methods. A vast 
majority of studies examining HIV and preterm birth are prospective or retrospective cohort 
studies, which utilize logistic regression to estimate odds ratios. Logistic regression assumes that 
the exposure is consistent across the specified observation period, which is often untrue in these 
data. In the context of HIV pregnancy, women can initiate treatment at any time during 
pregnancy, contributing both exposed and unexposed time to the overall gestational period. 
Women enrolled in cohort studies also usually have unequal observation times based on when 
she attends her first prenatal visit and could experience a competing event like miscarriage, 
which could erroneously exclude her from the risk set (depending on how cohort membership is 
specified). Time-to-event methods are best suited to deal with time-varying exposure, late-entry 
and competing risks, but few studies employ these methods to explore the effect of ART on 
preterm birth. 
And finally, the effect estimates derived are not always useful to clinical decision-
making. Studies regularly report statistical associations instead of endeavoring to make causal 
claims. Analysis methods which clearly approach making causal claims facilitate public health 
action and policy. A measure of association commonly reported in the literature is the odds ratio, 
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produced using logistic regression. Odds ratios tend to be commonly understood as risk ratios, 
even though odds overestimate the true risk.64,65  The margin of overestimation increases as the 
outcome becomes more common. This is problematic in the context of HIV-positive 
pregnancies, given that preterm birth is a relatively common outcome in this population. This is 
easily addressed by simply choosing a different model to directly estimate risk.  Additionally, 
estimating risk allows the effect to be presented as a risk difference, such that it is easily 
calculated and understood as the difference in risk between exposures of interest.66  
Another way to estimate effects using observational data is to emulate a target trial.67–70 
In the most literal sense, a target trial is a hypothetical RCT that we would wish to conduct under 
ideal circumstances. Thinking about studies in this way offers a useful heuristic to clarify the 
study design and the corresponding claims of effect we wish to make.67 When emulating a target 
trial with observational data, the target trial is the RCT we would design with the variables 
contained within the observational dataset we intend on using, assuming that the dataset contains 
sufficient information on confounders to approximate baseline randomization.68,69 If the 
emulation is successful, the results would be comparable to results from the target trial, had it 
been conducted.  The value in analyzing observational data using the target trial lens lies in the 
ability to approach causal inference explicitly, as opposed to the implicit (and perhaps informal) 
attempts at causal analyses using observational data.69   
2.5 Conclusion  
Our study is the first to explore the use of alternative epidemiologic analysis methods to 
promote interpretability and comparison across studies of observational data in the HIV and 
pregnancy space. It is also the first to explore the use of the emulated target trial approach using 
an HIV and pregnancy dataset to facilitate causal claims regarding the effect of ART on preterm 
birth. For Aim 1, we hypothesize that the effect of PI cART on preterm birth will not be different 
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than that among pregnancies exposed to other combination therapies.  The prevailing biological 
and epidemiological evidence suggests that the benefit of exposure to any combination ART 
regimen, irrespective of drug class, outweighs the alternatives of not being treated or treatment 
with monotherapy. Further, the harm conferred by PIs (as suggested by numerous studies) is 
likely due to methodological flaws in the current literature and not to an inherent pharmacologic 
quality that initiates premature spontaneous labor onset. For Aim 2, we hypothesize that in the 
emulated target trial analysis, the effect of PI ART on preterm birth will not be different than that 
among pregnancies exposed to other combination therapies, but will be protective compared to 
monotherapy. The emulated target trial uses an intent-to-treat approach by utilizing baseline 
exposures to estimate the causal risk ratio of the effect of ART on preterm birth.  
If ART regimen type is meaningfully associated with preterm birth in the WITS cohort, 
while utilizing appropriate methods and measures, the findings have the potential to influence the 
methodological approach of future HIV research.  Identifying and demonstrating the use of 
refined methods to motivate clinical practice and public health action can harmonize methods in 
the field of HIV and pregnancy. This would allow for comparisons between studies to be 
conducted more easily which would ultimately clarify evidence for HIV treatment policies and 
programs.  Preventing preterm birth and other adverse birth outcomes associated with ART can 
have a major public health impact by reducing infant mortality and morbidity, as well as 
protecting the reproductive goals of women living with HIV, and for their children and families. 
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2.6 Tables and Figures 
Table 2.1. HIV medications by drug class and year of FDA approval from 1987 to 2005 (Drugs 











ZDV – Zidovudine (1987) 
ddT – Didanosine (1991) 
3TC – Lamivudine (1995) 
ABC – Abacavir (1998) 
TDF – Tenofovir (2001) 
FTC - Emtricitabine (2003) 
SQV – Saquinovir (1995) 
RTV – Ritonovir (1996)* 
LPV – Lopinovir (2000) 
ATZ – Atazanavir (2003) 
FPV - Fosamprenavir 
(2003) 
DRV – Darunavir (2006) 
 
NVP – Nevirapine (1996) 





2 PIs - LPV/RTV - Kaletra 
(2000) 
3 NRTIs - ABC/3TC/ZDV – 
Trizivir (2000) 
2 NRTIs - TDF+FTC – 
Truvada (2004) 
1 NNRTI + 2 NRTIs - 
EFV/FTC/TDF – Atripla 
(2006) 
d4T - Stavudine (1994)  
 
IDV - Indinivir – (1996) 
NFV - Nelfinavir – (1997) 
APV - Amprenavir – (1999) 
DLV - Delavirdine (1997)  




Table 2.2  HIV treatment guidelines in the United States for adults and pregnant women from 1994 to 
2012.4,18,20 
Year Adults  > 18 years Pregnant Women 
1994  Initiate if CD4 < 200/ml 3-Part ZDV 
• Daily oral ZDV (starting 14-34 weeks gestation) 
• Intravenous ZDV during labor  
• Oral ZDV for infant 6 weeks postpartum  
1996 HAART if CD4 <350/ml  Treatment Naïve: 3-part ZDV Regimen  
Not Treatment Naïve: switch out NNRTI for ZDV if not already part of 
combination therapy  
2000 HAART if CD4 <350/ml or plasma HIV 
RNA > 10,000 copies 
Treatment Naïve: HAART + 3-part ZDV; can delay initiation until 
after 12 weeks gestation 
Not Treatment Naïve:  
• Switch out NNRTI for ZDV if not already part of combination 
therapy 
• Option to stop therapy prior to 12 weeks, and restart after 12 
weeks 
No treatment during gestation:  
• Single dose NVP at labor onset + single dose NVP to baby or; 
• Oral ZDV and 3TC during labor + one week of oral ZDV/3TC for 
newborn or; 
• Intravenous ZDV during labor + 6 weeks oral ZDV to newborn or; 
• 2-dose NVP with intravenous ZDV during labor + 6 week oral 
ZDV to newborn 
2004 • Initiate if CD4<350 and >200  
• For asymptomatic, treatment naïve 
patients with CD4+ T cell count >350 
cells/mm3, consider initiation if viral 
load is >55,000 copies  
No change 
2005 No change Treatment Naïve: same as adult guidelines, but avoid EFV/NVP 
Not Treatment Naïve:   
• After 12 weeks, switch to ZDV-based combination therapy  
• Women on NVP-based therapies should be monitored 
• Women on EFV-based therapies should be switched 
No treatment during gestation: 3-part ZDV 
2009 Initiate if CD4<500 No change 
2012 ART for all, irrespective of CD4 count No change 
14 
CHAPTER 3: RESEARCH DESIGNS AND METHODS 
3.1 Study Overview 
Overall, the objective of the study was to reexamine the methods used to understand the 
relationship between type of antiretroviral therapy on preterm birth among women living with 
HIV. We approached this objective in two ways using the Women and Infants Transmission 
Study (WITS). The first aim analyzed the effect of time-varying exposure to ART on preterm 
birth using survival methods. This is contrast to the analysis performed by the study team using 
logistic regression.3 We compared the effect of exposure to combination therapies No Therapy, 
ZDV monotherapy and NNRTI cART to PI cART initiated in pregnancy on preterm birth among 
women enrolled from July 31, 1996 to end of enrollment in 2005. The second aim estimated the 
causal effect of ART regimens on preterm birth among women enrolled in the larger cohort 
between 1990 and 2005 by emulating a target trial.67 These analyses answer similar research 
questions but demonstrate the use of two different analysis approaches to make inferences about 
ART use in pregnancy.  
3.2 Parent Study and Study Population  
The Women and Infants Transmission Study (WITS) is a US-based, multi-center, 
prospective, interval cohort designed to study the natural course of maternal-infant HIV-1 
infection. Between July 1989 and December 2005, HIV-positive pregnant women between the 
ages of 15 and 44, were eligible for enrollment on a continuous basis and at any point in 
gestation. The entire study population were confirmed to be HIV positive at the enrollment visit. 
Participants were tested using enzyme-linked immunosorbent assays (ELISA), with subsequent 
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HIV diagnosis confirmation using Western Blot.  Pregnancies were then followed-up at 
gestational weeks 18±2, 25±2, 34±2 and at delivery, corresponding to visits 1, 2, 3, and 4. Post-
partum, both infants and their mothers were followed-up at 4-6 months intervals until study end 
or they were lost to follow-up.  It was possible for the same women to be enrolled more than one 
time corresponding to multiple pregnancies.    
Prospective data collection included structured patient interviews and standardized 
clinical and laboratory assessments at each study visit. Retrospective data collection consisted of 
medical record abstraction.   Study sites included are hospitals in Boston, MA; Worcester, MA; 
New York, NY;  Houston, TX;  San Juan, PR;  and Chicago; IL. Informed consent was obtained 
for all women and infant participants according to each site’s local institutional review board, 
alongside federal guidelines for research. All prenatal care was at the discretion of the clinician. 
For the purposes of the proposed study aims, this is most important when understanding the 
circumstances of treatment decision-making (timing, switching and regimen type, etc.), as well 
as labor and delivery-related decisions (labor induction, methods of assisted delivery, cesarean-
section, etc.). The WITS cohort spanned nearly two decades of changing HIV-treatment 
guidelines, which also affected treatment decisions made by clinicians with their patients over 
time.   Women pregnant after 1996 were likely eligible for some version of HAART (hereafter 
referred to as cART), marking a period of relatively less variation in the recommended HIV-
treatment for pregnant women, and more comparable to treatment options available currently. 
3.3 Analytic Sample Construction 
For aim 1, we excluded women from the original study who were enrolled prior to 1996 
with the intention of analyzing pregnancies exposed to ART regimens relevant to clinical 
practice. PIs and NNRTIs are still currently prescribed, but given that the WITS study ended in 
2005 prior to the introduction of the new drug classes commonly used today (namely Integrase 
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Inhibitors), our analysis still considers outdated regimens in including ZDV monotherapy.  
Pregnancies were also excluded if they were exposed to ART at conception; were multiple 
gestation; ended prior to 20 weeks gestation; and if they enrolled after 28 weeks gestation. 
For aim 2, we identified eligible subjects based on articulating the ideal target trial to 
estimate the causal effect of ART initiated at 20 weeks gestation on preterm birth, and designing 
our trial emulation sample accordingly. The analysis sample therefore comprised of women 
enrolled into WITS between 18 and 22 weeks gestation at any time during the study period and 
whose pregnancies survived to 20 weeks.  Further detail on subject typology and exclusion 
criteria as they relate to pregnancy treatment guidelines are in Table 3.1.  
3.4 Gestational Age Assessment 
Gestational age (GA) is the underlying measure estimated for each pregnancy at entry, at 
each study visit, and at delivery. GA and length of pregnancy were calculated according to 
agreement between last menstrual period (LMP) as reported by the mother and first available 
ultrasound.72 In cases with disagreement between these two measures, GA was determined using 
ultrasound only and/or neonatal physical examination.    
3.5 Outcome Assessment  
Pregnancies can end at any point after conception. The timing of pregnancy termination 
is a key component in categorizing the type of birth outcome. Loss of the fetus prior to 20 weeks 
gestation is generally defined as an abortion and can be either spontaneous or elective. 
Spontaneous loss is commonly referred to as miscarriage. Live births between 20 and 37 weeks 
is considered preterm. Still births combined with live preterm births will also be considered as 
preterm in this analysis as a secondary outcome, given the shared causal pathway between ART 
exposure and delivery.  Extremely preterm is a subset of preterm birth defined as occurring 
between 16 weeks 0/7 days and 28 weeks 6/7 days gestation.  Births are considered very preterm 
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if they occur between 28 weeks 0/7 days and 31 weeks 6/7 days gestation; and late preterm 
describes births occurring between 32 weeks and 36 weeks 6/7 days.  
Preterm birth can occur either spontaneously or due to medical intervention, known as 
iatrogenic birth. Iatrogenic births are initiated by the clinician in the presence of possible risks to 
the mother or infant, such as preeclampsia, infection, or abnormal fetal testing. Due to the 
possible differences in causal pathways between births occurring spontaneously and due to 
medical intervention, reporting the risk of spontaneous preterm birth only could further clarify 
the effect of PI cART   We have therefore identified only those preterm births that could be 
affected by ART exposure in pregnancy, either occurring by spontaneous onset of labor or 
medically indicated delivery due to an underlying condition known to be associated with ART.  
Women carrying more than one fetus have a higher risk for experiencing a range of pregnancy 
complications that could lead to poor birth and infant outcomes. Since we are not interested in 
this particular causal pathway for the proposed analysis, multiple gestation pregnancies were 
excluded for all aims. 
3.6 Exposure Assessment  
Information pertaining to time of ART use in the 12 months prior to enrollment were 
collected at enrollment visits and for each study visit based on medical record abstraction. If 
medical records were unavailable, information on ART use was based on subject recall. Time 
was collected as month and year and then converted to months since enrollment or months since 
diagnosis in the dataset. Exact dates of treatment initiation and stopping treatment were not 
recorded. Time was later transformed into gestational weeks. Exposure to ART is relevant for all 
three study aims. Exposure definitions for the proposed analysis have two components – timing 
of exposure and regimen type.  
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3.7 Timing of Exposure 
For both aims, timing of treatment initiation depended mainly on disease severity 
measured by CD4 count and/or viral load at the time. Table 3.1 describes the types of subjects in 
WITS based on possible treatment plans CD4 thresholds between 1996 and 2005 and timing of 
initiation. If a woman living with HIV was diagnosed prior to pregnancy, she could have 
initiated treatment if she met the disease severity thresholds, being preconceptionally exposed to 
ART. In contrast, women who were diagnosed with HIV but did not meet the disease severity 
threshold at the time of diagnosis, or those who were diagnosed in pregnancy were likely to have 
not been initiated irrespective of CD4 count or viral load. Pregnant women living with HIV 
could be initiated at any time during pregnancy at the discretion of her clinician. Only women 
starting HIV treatment in pregnancy were analyzed in this study.  
While the exact date of initiation and date of conception are unknown in these data, we 
assumed that that women initiating HIV treatment prior to enrollment in WITS were on 
treatment while conceiving. Women who were exposed to ART in pregnancy without evidence 
of having been exposed prior to enrollment were assumed to have been unexposed to ART at 
conception and were included in the analysis for both aims (Types 3, 4 and 5 in Table 3.1). Table 
3.1 describes the possible scenarios of treatment initiation, given the CD4 thresholds for 
initiation at the time, the data that are available, and the assumptions we made to categorize 
initiation time. Exposure was considered time-varying for Aim 1, and baseline exposure was 
carried throughout gestation to delivery, approaching an intention-to-treat analysis for Aim 2.  
3.8 Regimen Types 
The proposed analysis focuses on the effect of PI-based ART compared to other 
exposures pregnant women had during the study period.  A significant proportion of women in 
the parent study did not receive any therapy until later in pregnancy or at delivery. This is 
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consistent with the introduction of novel ART regimens in the mid-1990s.  For Aim 1, we 
defined exposure using data collected at each study visit, based on both patient recall and 
medical record abstraction. Each study drug was entered into the database with a start date and 
stop date. These times were converted into “time since enrollment” values. We then 
reconstructed multi-drug, combination regimens using the start and stop dates to define our study 
exposures. If a pregnancy were exposed to a regimen for less than two weeks, it was discarded 
and the regimens on either side of this <2 week window split the difference.  Because the 
purpose of WITS was to study the natural course of HIV in pregnancy in the context of changing 
therapy guidelines, we thought it safe to assume that no drug data meant that the woman was 
unexposed to treatment; not that treatment data were missing.  
Therefore, pregnancies exposed to at least one PI with at least two NRTIs were 
categorized as PI cART exposure; at least one NNRTI with at least two NRTIs was categorized 
as NNRTI cART. ZDV exposure without other accompanying drugs or reported concurrently 
with either PI- /NNRTI- cART was categorized as monotherapy; and gaps in treatment were 
considered as exposure to no therapy. ZDV monotherapy was the standard of care during 
pregnancy prior to the discovery of combination regimens. These categorizations are further 
detailed in Appendix B.  After 1996, ZDV monotherapy was given concurrently to cART 
regimens. For both aims, if a pregnancy was exposed to both a combination regimen and ZDV 
monotherapy, the combination regimen was prioritized for categorization. For the Aim 2 analysis 
emulating a target trial, we considered baseline exposure only. This meant that among women 
who were eligible and unexposed to treatment at conception, women were separated into 
exposure groups based on their treatment regimen at enrollment, occurring among women 
enrolling between 18 and 22 weeks gestation. The exposure groups considered for the emulated 
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trial were identical to that defined for Aim 1 – No Therapy, PI cART, ZDV monotherapy and 
NNRTI cART.   
3.9 Covariate Assessment  
Covariates detailed in Table 3.2 were measured during study follow up and will be 
considered in estimating effects in the proposed analyses.  Because this dataset is publicly 
available, certain variables have been recategorized or omitted to protect subject privacy, 
especially since so few infants were born with HIV in the later years of the study. Therefore, 
study site has been removed entirely from the dataset, and exact year of birth has been 
categorized as “1996+” for all births occurring 1996 and onward. Other potentially relevant 
variables, such as maternal educational attainment and insurance status were collected but not 
included in the cleaned WITS analysis datasets.  Additional covariates relevant to specific aims 
are described in the corresponding sections below.  The causal pathway for each aim is described 
using a causal diagram represented as a directed acyclic graph (DAG) in Appendix A. Covariates 
determined to be part of the minimally sufficient adjustment set were included in the final effect 
estimates.  
• Functional Form Assessment of continuous variables: We used restricted quadratic 
splines with four equally placed knots for all continuous variables for the final adjusted 
models. 
• Effect Measure Modification (EMM): EMM will not be considered for either analysis 
aim.  
• Missingness: We assessed whether missing values of covariates are conditional on either 
the exposure or outcome, and subsequently whether it introduces bias to the effect 
estimate.  If baseline values were assumed to be missing at random, multiple imputation 
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or inverse probability weights were used to account for these missing data, depending on 
the analysis model used for the primary analysis. If analysis showed there was systematic 
missingness in the data, we conducted sensitivity analyses to assess if the missingness 
posed a material threat to the study findings. This is described in further detail by aim in 
the following sections.  
3.10 Aim 1 Statistical Analysis 
First, we summarized important maternal baseline characteristics. We the estimated the 
unweighted and weighted cumulative incidence and risk differences (RD) of preterm birth at 37 
weeks using the complement of the Kaplan-Meier estimator given exposure to a category of HIV 
treatment (Formula 1). Inferences are conditional on survival to 20 weeks gestation. The origin 
for each pregnancy was the date of enrollment or the date of first treatment in pregnancy, 
whichever occurred first, and the timescale was gestational weeks until end of 
pregnancy/delivery. There was no right censoring or loss to follow up because all pregnancies 
were followed until pregnancy end.  
Formula 1: Kaplan-Meier estimator for cumulative incidence 







?̂?𝐾𝑀 is risk of preterm birth as estimated by the complement of the Kaplan-
Meier estimator. t is a given time; Rk is a time when at least one birth occurred; 
dk is the number of births that occurred at time Rk; and nk is the number of 
fetuses known to have survived up to time Rk. HIV treatment is the exposure of 
interest, and z is an exposure category within Z.    
 
Time-to-event methods are appropriate for this research question because we wanted to 
estimate the risk of birth relative to advancing gestational age, accounting for both late entry and 
time-varying exposure. Pregnancies could contribute gestational weeks to any of the exposure 
groups depending on their exposure status at any given time during gestation. Exposure-
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switching is handled by censoring a pregnancy at the time of treatment switching; the 
observation time then moves to the treatment to which she switched.  To estimate the risk and 
risk difference of PI cART compared to both no treatment, ZDV monotherapy and NNRTI 
cART, we used the cumulative incidence at 37 weeks, 32 weeks and 28 weeks to calculate 
absolute risk differences, using PI cART as the common reference. Weighted estimates reflected 
the changing treatment regimens over gestation and to produce a visual representation of the 
changing risk over time, accounting for confounding. The visual representation of the weighted 
risk curve is the counterfactual scenario had pregnancies been exposed to one treatment 
throughout gestation.  
We used stabilized IPW to control for confounding. If confounders had missing values, 
we identified important predictors of missingness and included them in a pooled logistic 
regression model with missinginess as the outcome. We then used the resulting model 
parameters to generate a stabilized IPW for missingness. This missingness weight was then 
applied to a multinomial logistic regression model (the propensity score model) to generate a 
stabilized IPW for the confounder with missing values. If a confounder did not have missing 
values, we directly estimated stabilized IPW for treatment using a similar propensity score model 
as described previously. The final analysis weight was the product of the missingness and 
treatment weights.  
Since we utilized nonparametric methods to estimate risk, we generated 95% confidence 
intervals for risk and risk difference estimates using 200 bootstrapped samples (with 
replacement). We arrived at the number of bootstrapped samples by considering the distribution 
and variance of the bootstrapped effect estimates. We also conducted sensitivity analyses to 
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randomly choose one pregnancy for inclusion into the analysis sample if a woman contributed 
more than one eligible pregnancy to see if the effect estimates materially changed.  
3.11 Aim 2 Statistical Analysis 
To estimate causal effects, we designed our analysis for the emulated trial to be 
comparable to that to the target trial. We first summarized maternal baseline characteristics 
stratified by exposure group. We then used a log-Poisson model to approximate the log-binomial 
model in order to estimate risk ratios (RR) for the effect of ART on preterm birth, for both the 
conditional and unconditional analyses (Formula 2).73 A Poisson model was used because the 
adjusted log-binomial model failed to converge.74 Generalized estimating equations (GEE) with 
an exchangeable correlation matrix were used to generate 95% confidence intervals. We 
accounted for confounding by including important baseline confounders to emulate 
randomization in the statistical model.   
Formula 2: Poisson regression model 
𝑙𝑜𝑔𝑃(Preterm Birth = 1) = α + 𝛽1(𝐴𝑅𝑇 𝐸𝑥𝑝𝑜𝑠𝑢𝑟𝑒) +  𝛽2𝑋2 
 
Where X is a matrix of potential covariates in the final adjustment set.  
 
For the emulated target trial analysis, RRs were estimated for the effect of baseline ART 
on preterm birth, comparing each exposure group to PI cART as the reference. We conducted 
two analyses, one assuming that exposure was unconditional (like a true RCT) and another 
analysis assuming that exposure was conditional on baseline covariates (a more realistic scenario 
since these data are drawn from an observational cohort.) We identified important baseline 
covariates using the target trial eligibility criteria and analyzed a DAG to identify a minimally 
sufficient adjustment set (Appendix A).  
To better understand the scope of missingness in the data, we summarized baseline 
covariates stratifying by complete and incomplete cases. While we had complete exposure and 
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outcome data, there were several baseline confounders we included in our multivariate models 
which had missing values and a complete case analysis would dispense of more than 50% of the 
sample.  We therefore used MI for each analysis separately to impute missing covariate values.75  
We used fixed chain equations and included predictors of missing values that were used in the 
analytic models for the main effect, as well as auxiliary variables to improve the overall fit of the 
imputation model.76 We then generated 30 imputed datasets for each analysis and ran the 
multivariate analysis model on each imputed dataset. Rubin’s rules was used to pooled the 
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Table 3.2 Measured covariates considered for analysis for Aims 1 and 2. 
 Variable Name  Definition  Frequency of measurement  Method of 
Measurement  
1 Gestational Age Time since conception 
in weeks  
 
Each study visit including 
delivery 
Subject recall of last 







Asian, and Other  
 
Enrollment  Self-report  
3 Maternal Weight  In kilograms Each study visit Measured using a 
standard scale; weight at 
enrollment was included 
in analysis 
4 Maternal Age  Years since birth  
 










Each study visit  Self-report 











Each study visit  Self-report and urine test 
7 CD4 Count  Continuous measure 
expressed as the 
number of CD4 T 
lymphocyte cells per 
cubic micromilliliter 
(mm3) of blood. HIV 
infection targets 
primarily CD4 cells; 
HIV treatment 
promotes immune 
recovery, indicated by 
increasing CD4 levels 
once treatment is 
initiated.   
 
Collected at each study visit, 
medical abstraction 
Collected blood samples, 
upon which flow 
cytometry was conducted 
at laboratories certified 
by the NIAID 
Immunology Quality 
Assurance Program 
(Adult AIDS Clinical 
Trials Group, 2006a) 
8 Viral Load  Continuous measure of 
the number of copies of 
HIV RNA per milliliter 
of blood. The goal of 
HAART is to suppress 
viral load to “below 
detection” by the test; 
viral load values <400 
are considered 
undetectable for the 
proposed study. 78   
 




9 Diabetes During 
Pregnancy 
Categorical, Yes/No Confirmed at last visit prior 
to delivery, corresponding to 
28 or 34 week visit  
 
Measured by glucose 








11 Hypertension During 
Pregnancy 
Categorical, Yes/No Confirmed at last visit prior 
to delivery, corresponding to 
25 or 34 week visit  
 
Blood pressure reading in 
excess of 140/90 mm Hg 
and either a blood test/ 
urine analysis/ fetal 








Categorical, Yes/No  Collected at each study visit   Standardized laboratory 
testing to determine 
whether woman was 
infected with bacterial 
vaginosis, trichomonas, 
or syphilis.  
 
13 Cohort time  Describes the time 
during which the 
pregnancy occurred 
during follow-up, 
categorized into the 
following: prior to 
2/28/1994; 3/1/1994 to 
7/31/1996; and after 
7/31/1996 
corresponding to HIV 
treatment eras.  
 





CHAPTER 4: AIM 1 - PROTEASE INHIBITOR-CONTAINING ART REGIMENS AND 
PRETERM BIRTH: A REEXAMINATION USING SURVIVAL ANALYSIS METHODS 
4.1 Introduction 
Worldwide, preterm birth is associated with 75% of perinatal mortality and more than 
half of long-term morbidity of children, including cognitive disability, poor motor skills, 
behavioral problems, hearing loss and chronic lung disease.33–36 The causes of preterm birth are 
complex, particularly among women living with HIV. Women living with HIV in the United 
States are at high risk for preterm birth (PTB) not only due to HIV infection itself,79 but also 
because they experience other preterm birth risk factors like gestational diabetes and gestational 
hypertension; 3,38 alcohol and drug use;37,39 and smoking cigarettes both prior to and during 
pregnancy at higher rates than women without HIV infection.40  
An increasing number of HIV-infected women of reproductive age are initiating 
antiretroviral therapy (ART) worldwide. Because of this, the number of women on treatment 
before and during pregnancy is increasing.37,80 Antiretroviral therapy (ART) significantly 
reduces the risk of HIV transmission from mother to child, however several studies suggest that 
ART can cause preterm birth.48,81  Understanding the possible consequences of HIV treatment on 
preterm birth is therefore of urgent importance in the growing population of reproductive-aged 
women living with HIV.  
Several studies investigating the relationship between ART and preterm birth have found 
that regimens containing protease inhibitors (PI) are associated with preterm birth.43,48,81–83  
However, other studies show no differences in preterm birth occurrence by ART regimen. 57,84,85  
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Reconciling these conflicting findings has been a research challenge over the past decade. 
Controlling HIV infection through ART minimizes the inflammatory response to systemic 
infection, thereby lowering preterm birth risk.86,87 Use of ART in pregnancy would therefore be 
expected to reduce, rather than increase, the risk of preterm birth.54,55   Even so, it is possible that 
certain ART drugs – while preventing transmission of HIV – induce inflammation through 
immune reconstitution that could cause premature initiation of the labor cascade.38 There is 
evidence that Lopinavir and Nelfinavir – both PIs – show declining bioavailability in the third 
trimester compared to levels prior to pregnancy.88,89 This means that viral suppression may not 
be maintained in later gestational weeks, and could cause a reemergence of infection-associated 
inflammation and the accompanying risk of preterm labor onset.90 PIs are also associated with 
adrenal dysfunction and metabolic disturbances (i.e. diabetes, hyperglycemia) in pregnant 
women, which are also associated with preterm birth.91–93   
Studies showing PI-based regimens to be harmful may not have sufficiently accounted 
for confounding by indication, given that PI-based regimens were often reserved for individuals 
with more severe disease.94,95 Another explanation for the discrepancies could be the 
methodological flaws in analyzing data from observational HIV pregnancy cohorts. Treatment 
misclassification caused by intent-to-treat approaches96 or conditioning on future exposures,63  
and selection bias induced by excluding untreated pregnancies are common analytic limitations 
in the HIV and pregnancy literature.56  Additionally, studies in the current literature tend to not 
show the changing risk of preterm birth in pregnancy, which is important in understanding how 
exposures affect pregnancy and birth during gestation.  
The primary objective of this study is to reexamine the effect of PI-containing 
combination ART (cART) on the risk of preterm birth using methods that account for important 
 
30 
facets of observational pregnancy cohorts.   We estimated the risk of preterm birth by ART 
regimen using the complement of the Kaplan-Meier estimator which accommodates treatments 
that change during observation (time-varying exposure). Given that these data are derived from 
an observational context, the use of survival analysis methods also allows us to account for late 
entry into the cohort and to examine the changing risk of birth over the entire gestational period 
by exposure to offer further context pertaining to the reported differential effects of PI ART 
compared to other regimens on preterm birth.  
4.2 Methods 
We used publicly available data from the Women and Infant Transmission Study 
(WITS). WITS was a US-based, multi-center, prospective, interval cohort designed to study the 
natural course of maternal-infant HIV-1 infection between 1990 and 2005. 1,2  Prospective data 
collection included structured patient interviews and standardized clinical and laboratory 
assessments at each study visit. Retrospective data collection consisted of medical record 
abstraction. WITS study sites were hospitals located in Boston, MA; Worcester, MA; New York, 
NY; Houston, TX;  San Juan, PR;  and Chicago, IL. The entire study population was confirmed 
to be HIV positive at the enrollment visit. Participants were tested using enzyme-linked 
immunosorbent assays (ELISA), with subsequent HIV diagnosis confirmation using Western 
Blot.  Informed consent was obtained for all women and infant participants according to each 
site’s local institutional review board, following federal guidelines for research. Study visits 
coincided with antenatal visits and all prenatal care was at the discretion of the clinician. This is 
most important when understanding the circumstances of treatment decision-making (e.g., 
timing, switching and regimen type), as well as labor and delivery-related decisions (e.g., labor 
induction, methods of assisted delivery, cesarean-section). Additional study details for the WITS 
parent study are published elsewhere.1,2   
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While questions pertaining to the association of ART and preterm birth have been 
previously explored in WITS,2 this study differs from past work in the following ways: First, we 
estimate risk differences of preterm birth by exposure while accommodating late-entry into the 
cohort and time-varying exposure by utilizing survival (time-to-event) methods instead of 
conventional binary methods (e.g., logistic or log-binomial regression). Binary methods are 
useful when both the observation time and exposure plans are known and fixed. Observational 
settings are by definition non-interventional, meaning the observation time and exposure plans 
are both variable. In such settings, survival methods flexibly accommodate late-entry, time-
varying exposure and censoring, while binary methods do not account for these elements as 
easily. Survival methods also provide additional context that is often lacking in the available 
literature describing ART and birth outcomes by visualizing events over time. Second, we 
analyze a subset of WITS pregnancies occurring between 1996 and 2005 i.e. in the era of 
combination regimens known as highly-active antiretroviral therapy. Restricting the analysis to 
the current treatment era facilitates the results to be more relevant in the current clinical context. 
(We will refer to combination regimens in this paper as cART.) Third, we utilize a causal 
diagram97 to guide final covariate adjustment to facilitate interpretation of results based on 
substantive evidence, in contrast to stepwise covariate elimination or other related, statistics-
driven methods. 
4.3 Study Population 
We included singleton pregnancies occurring between 1996 and 2005 among women 
living with HIV (aged 15 – 45) that survived past 20 weeks gestation and enrolled prior to 28 
weeks gestation. We conditioned on fetal survival to 20 weeks to remove the possibility of 
miscarriage as a competing event. (Figure 4.1) Pregnancies enrolling at points B or C were 
eligible for analysis.  Pregnancies unexposed to ART at the enrollment visit were included, under 
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the assumption that those unexposed at enrollment were likely unexposed to ART at the time of 
conception. Gestational age (GA) was estimated for each pregnancy at entry, at each study visit, 
and at delivery. GA and length of pregnancy were calculated according to agreement between 
last menstrual period (LMP) as reported by the mother and first available ultrasound.72  In cases 
of disagreement between these two measures, GA was determined using ultrasound only and/or 
neonatal physical examination.  
4.4 Outcome Classification 
Pregnancies ending in either live birth or stillbirth (hereafter referred to as “birth” or 
“delivery”) between 20 weeks and 36 6/7 weeks were considered preterm. We included 
stillbirths in the outcome of interest because it is an adverse outcome that could plausibly be 
caused by ART exposures. All stillbirths in the analytical sample occurred prior to 37 weeks 
gestation. Secondary outcomes of interest were very preterm birth (< 32 weeks) and extremely 
preterm birth (<28 weeks).98  Births occurring on or after 37 weeks were considered term.   
4.5 Exposure and Confounder Classification 
Timing and type of exposure were ascertained at each study visit through structured 
patient interviews, medical chart review and retrospective medical record abstraction when 
available. Treatment data were recorded as single drugs and the corresponding start and stop of 
exposure expressed as months since enrollment. At the enrollment visit, the clinician either 
prescribed ART or allowed pregnancies to proceed without treatment until the next visit, when 
the treatment plan could be reconsidered. We were unable to confirm if women were ART-naïve 
at enrollment due to incomplete data on treatment history and timing of HIV diagnosis. Exposure 
to a regimen for less than two weeks was considered too short of a window to have any impact 
on birth outcomes.99 Consequently, the exposure was removed and exposures on either side of 
the <2 week window equally closed the gap.  
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ART exposures considered in this analysis are regimens comprised of either a single drug 
or combination of drugs drug classes prescribed at a given time.  Exposure regimens considered 
in this study are PIs; nucleoside reverse transcriptase inhibitors (NRTIs); and non-nucleoside 
reverse transcriptase inhibitors (NNRTIs). Exposure categories are defined as the following four 
mutually exclusive groups: no therapy, Zidovudine (ZDV) monotherapy; PI-based cART; 
NNRTI-based cART; and “mixed” therapies defined as including both PIs and NNRTIs 
prescribed concurrently. ZDV monotherapy was the standard of care for pregnant women during 
the investigated timeframe and was often prescribed concurrently with cART.22 When both ZDV 
and cART were prescribed together, women were categorized as exposed to cART. (Appendix 
B).  
Baseline information about each pregnancy was collected at the enrollment visit through 
standardized enrollment questionnaires. Race/ethnicity was classified into four racial categories 
(American Indian or Alaskan Native, Asian or Pacific Islander, Black, and White) and two ethnic 
categories (Hispanic origin, and Not of Hispanic origin) as per the 1996 U.S. Census Bureau. 
Racial and ethnic categories were combined into a single race/ethnicity category in the WITS as 
White, Black, Hispanic and other (including Native American/Alaskan Native and Asian/Pacific 
Islander).  Body mass index (BMI) was calculated using weight and height at enrollment visit. 
The following covariates were all coded dichotomously as yes/no: history of diabetes and 
hypertension; use of cigarettes, marijuana, crack/cocaine, heroin and alcohol in pregnancy; 
coinfection with syphilis or chlamydia during pregnancy; and presence of AIDS-defining illness.  
For this study, access to prenatal care described whether a pregnancy was exposed to at least one 
prenatal visit prior to 28 weeks gestation. Baseline viral load measurements were taken at 
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enrollment, corresponding to either the 12- or 24-week appointment. Baseline viral load and 
maternal age were modeled continuously as restricted quadratic splines with four equal knots.100 
We used a DAG to identify a minimally sufficient adjustment set of confounders.  The 
final adjustment set included access to prenatal care, baseline viral load, baseline maternal age, 
AIDS-defining illness and study site. These confounders are accounted for through restriction 
(access to prenatal care) and standardization (baseline viral load and maternal age). Only three 
pregnancies had an AIDS-defining illness so this confounder was removed from the adjustment 
set. Study site was also not considered in the analysis because this variable was removed from 
public-use dataset to preserve the confidentiality of study participants. Prior preterm birth is 
often adjusted for in analyses of exposures and preterm birth but we excluded this from the 
DAG.101 Prior preterm birth is a proxy for other underlying biological factors causing preterm 
birth, but prior preterm birth itself is unlikely to have a causal link to the exposure of interest or 
timing of delivery.  
4.6 Statistical Methods 
We used inverse-probability-of-exposure weighted risk curves using the complement of 
the Kaplan-Meier estimator to estimate cumulative incidence and risk differences of preterm 
delivery by time-varying exposure. PI cART was the reference group for all risk difference 
measures. In these analyses, each pregnancy was followed from the week of enrollment until the 
week of delivery. There was no right-censoring or lost-to-follow up because all pregnancies were 
followed until the end of pregnancy.  
Controlling for access to prenatal care was done through sample restriction. Stabilized 
inverse probability weights (IPW) were used to account for missing baseline viral load values, as 
well as to control for confounding by baseline viral load and maternal age.   The numerator and 
denominator of the missingness weights were calculated using logistic regression and included 
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maternal age at enrollment, baseline ART, race/ethnicity and gestational age at study entry as 
predictors. We calculated treatment weights for viral load and maternal age using pooled 
multinomial logistic regression. The missingness weight was included in the treatment weight 
calculation for viral load. The final analysis weight was the product of the IPWs for missing 
baseline viral load, confounding by viral load and confounding by maternal age. We accounted 
for tied event times using the exact method. Confidence intervals for risk differences were 
calculated using the standard deviation from a bootstrap of 200 samples (with replacement) from 
the observed data.  
Pregnancies were allowed to switch exposure categories in gestation. In the crude 
Kaplan-Meier context, the pregnancy was censored at each point of exposure-switching and 
continued on another curve corresponding to the new exposure. The weighted time-varying 
exposure Kaplan-Meier risk curves illustrate the counterfactual scenario had pregnancies been 
exposed to only one treatment from enrollment to delivery, accounting for measured 
confounding using weights. Exposure contrasts comparing regimens containing both PIs and 
NNRTIs (“mixed therapies”) to regimens of interest are not reported in this paper since it is a 
highly heterogeneous exposure group, and comparisons to it are not useful to future policy.    We 
were unable to exclude pregnancies exposed to mixed therapies entirely. Several pregnancies 
were exposed to both mixed therapies and exposures of interest, and it was necessary to account 
for all changing treatment plans in the time-varying exposure analysis.  
 We conducted two sensitivity analyses to explore whether risk estimates changed 
materially under the following scenarios. Because the Kaplan-Meier estimator does not account 
for clustered data, we randomly selected one pregnancy for inclusion from each woman 
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contributing more than one pregnancy to the analysis sample. We also excluded pregnancies with 
missing singleton status.  
4.7 Results 
Of the 3,297 pregnancies included in the WITS parent study, 1,270 were excluded 
because they were enrolled prior to 1996. Among the remaining pregnancies, 48 were excluded 
because they were multiple gestation, 765 were excluded because the pregnancy ended prior to 
20 weeks gestation or were enrolled after 28 weeks gestation, and 147 were excluded because the 
pregnancies were exposed to ART at conception. Therefore, a total of 1,067 HIV-positive 
pregnancies in 932 women were followed until delivery (Figure 4.2).  
Enrollment in the WITS analysis sample occurred between 12 and 21 weeks gestation 
(median 17 weeks). Approximately 42% of women included in the analysis sample were Black 
(N = 446) and a third were Hispanic (N = 359).  Fifty-three percent of women were between the 
ages of 25 and 34 (N =569), and the median BMI at enrollment was 26.9. Drug and alcohol use 
in pregnancy was common in this population, with 31% reporting use of cigarettes (N=329), 
20% reporting alcohol consumption (N = 213) and 20% using hard drugs (N = 211). (Table 4.1).  
 Twenty-four per cent of pregnancies had viral load <400 copies/ml3 indicating viral 
suppression at enrollment (N = 236). All pregnancies were unexposed to ART at conception, of 
which over half remained on no therapy beyond the enrollment visit (N = 545). At the enrollment 
visit, 22% of pregnancies were prescribed PI cART (N = 232), 20% were started on ZDV 
monotherapy (N = 216) and 3% were prescribed NNRTI cART (n = 32). Total observed 
gestational weeks contributing to effect estimates for PI cART was more than seven times that 
for NNRTI cART (6778 weeks versus 940 weeks). By the end of follow-up, 29% of pregnancies 
had switched treatment regimens at least once (Table 4.1).  Thirteen percent of deliveries 
occurred in week 37 (N=137) and 29% occurred in week 38 (N = 304) (Figure C.1). The median 
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gestational age at delivery was 38 weeks, and 18% were delivered prior to 37 weeks (N = 192) 
(Figure C.2).  
As expected, risk of preterm birth (<37 weeks) was highest among pregnancies exposed 
to no therapy (risk: 23%; 95% CI: 19%, 26%). After adjusting for confounding, the risk of 
preterm birth was comparable between no therapy and ZDV monotherapy at approximately 20%, 
followed by PI cART at 17% and NNRTI cART at 7% (Table 4.2 and Figure 4.3A). The 
unweighted preterm birth risk for NNRTI cART was 12 percentage points lower than that for PI 
cART (RD: -12%; 95% CI: -18%, -6%). After applying inverse probability weights to correct for 
missing data and confounding, the difference was attenuated slightly to 10 percentage points 
(RD: -10%; 95% CI: -21%, 2%), though the confidence interval remained wide and included the 
null value (Table 4.2 and Figure 4.3A). We found there to be no meaningful difference in risk of 
preterm birth between PI cART and ZDV monotherapy in either the unweighted [RD: 0%; 95% 
CI: -3%, 4%] or weighted [RD: 3%; 95% CI: -2%, 8%] estimates.  
In examining deliveries occurring very preterm (<32 weeks), exposure to PI cART was 
associated with the lowest preterm birth risk while exposure to no therapy was associated with 
the highest risk in the unweighted and weighted analyses. (Table 4.2 and Figure 4.3B). There 
was a significant difference in weighted risk estimates comparing both No Therapy (RD: 3%, 
95% CI: 1%, 6%) and ZDV monotherapy to PI cART (RD: 3%, 95% CI: 1%, 5%).  The 
incidence of birth prior to 28 weeks was very low in this cohort (indeed, no women exposed to 
NNRTI cART delivered prior to 28 weeks), thus we were unable to make meaningful 
comparisons around this gestational age cut-point.   
The unweighted risk curves show the crude time-to-delivery by exposure, allowing for 
changing exposure over gestation (Figure 4.4). The weighted time-varying exposure risk curves 
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(Figure 4.5) stratified by exposure show separation between 20- and 35-weeks with no therapy 
and ZDV monotherapy exposures showing a higher proportion of deliveries in earlier gestational 
weeks than both cART regimens. While PI cART risk curve is higher than the NNRTI cART 
curve throughout gestation, the curves cross at week 34.  
None of the above results were materially changed by restricting the sample to a single 
pregnancy per woman in sensitivity analyses. Thirty-six pregnancies had missing data 
confirming singleton status (3.4%), but including them did not significantly affect risk estimates 
either. Results from the sensitivity analyses are shown in Appendix C.  
4.8 Discussion 
As expected, combination ART therapies are not associated with increased risk of 
preterm birth compared to ZDV monotherapy, as presented in the original WITS publication.3 
The effect estimates for very preterm birth and the risk curves produced by the complement of 
the Kaplan-Meier estimator confirm that suppressive regimens confer protection against preterm 
births at lower gestational ages in contrast to pregnancies exposed to monotherapy and no 
treatment, and continue to have a protective effect throughout gestation.  Non-suppressive 
regimens are no longer prescribed or clinically relevant due to evolving HIV treatment 
guidelines.102 
Results presented in Figure 4.3 suggest that PI cART, while protective overall compared 
to no ART, is relatively harmful when compared to NNRTI cART, consistent with several other 
studies.59,95,102,103 However, Figure 4.5 shows the weighted risk curves crossing between 32 and 
37 weeks, calling into question that PI cART is definitively harmful. These results show that 
even if preterm birth risk is reported at 37 weeks and 32 weeks, the risk could change between 
these two time points, offering important context to the overall effect of ART on preterm birth 
risk. In these data however, it is more likely that the risk curves crossing is due to the small 
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sample size of NNRTI-exposed pregnancies. Having small sample sizes of NNRTI-exposed 
pregnancies compared to PI-exposed pregnancies is common among observational pregnancy 
cohorts, further lending to the challenges in understanding the comparative risk of preterm birth 
between PI- and non-PI- containing regimens.59,104,105  
The numerous studies implicating PI cART utilized binary regression to report odds 
ratios or risk ratios at gestational weeks consistent with conventional delivery-timing 
classification at 28-, 32- and 37 weeks. Because our study employs non-parametric survival 
methods to estimate risk, we are able to report risk both in terms of delivery-timing 
classifications, and as a dynamic risk function by exposure over time as shown in Figures 4.4 and 
4.5.  The risk curves support better interpretation of risk over time, apart from the rigid preterm 
birth classifications. In our study, cumulative incidence of preterm delivery at 37 weeks among 
PI cART-exposed pregnancies was higher than those exposed to NNRTI cART, but NNRTI 
cART risk estimates had undesirably wide confidence intervals containing the null value. This is 
likely because pregnancies exposed to NNRTI cART contributed the least number of person-
weeks to the overall time at risk for delivery and only two births occurred during NNRTI cART 
exposure. At the time of the study, PI-based regimens were more frequently prescribed than 
NNRTI- regimens because there were far more PI drugs approved by the Federal Drug 
Administration.  
This study was limited in ways similar to those of many observational HIV pregnancy 
cohorts. First, enrollment in WITS was limited by the timing of pregnancy detection and linkage 
to antenatal care. Ideally, pregnancies would have been enrolled from conception (or before)106 
with complete ART treatment history information from HIV diagnosis. Without complete HIV 
diagnosis and treatment history, we were unable to definitively confirm timing of ART initiation 
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as it related to conception. Both nadir CD4 count (typically the CD4 count at HIV diagnosis) and 
timing of treatment can affect risk of preterm birth among pregnant women living with HIV. The 
available dataset did not include study site, so were unable to account for site-specific 
differences in prescribing patterns and severity of disease.  
Second, measurement error across a few key variables could be a source of bias in this 
analysis as well. Challenges in measuring gestational age accurately and the accompanying bias 
in its measurement are well-documented in the literature, and we suspect this bias to be present 
in our study as well.107,108 More than 40% of all deliveries occurred in weeks 37 and 38, just 
missing the preterm birth cutoff (Figure C.1). It is likely that the timing of exposure to ART 
regimens could potentially be a source of bias in this analysis as well. Actual dates are not 
provided in the dataset; instead, the usage periods are bounded by “time from enrollment in 
months.” For records only containing the month and year, days were imputed as “15”. Further, 
our time-varying exposure analysis assumes that there is no cumulative effect of the exposure on 
the outcome. Even though our analysis did not examine the effect of exposure duration on 
preterm birth per se, estimates should still be interpreted with caution due to the lack of reliable 
start and stop dates for treatment.  Third, our analysis assumes no unmeasured confounding - 
strong assumptions that may not be valid. However, we considered a host of potential 
confounders based on an extensive review of the literature, and using causal diagrams included 
those which were causally important.  
A primary strength of this study is demonstrating the use of nonparametric survival 
methods to show changes in preterm birth risk over time. Preterm birth risks estimated using 
regression and reported at one or two cut-points can obscure changes in risk at intervening 
gestational ages which could be potentially important. Further, this method accounts for 
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changing exposures over the risk period, approaching a per-protocol analysis. While left 
truncation bias is a challenge in virtually all pregnancy cohort studies (including ours since we 
allow for late-entry between 20 and 28 weeks) our study mitigates the bias by restricting to 
pregnancies unexposed to ART at conception and surviving to 20 weeks. We also report effects 
in absolute terms which are easily interpretable.   
The challenge in reaching a clear understanding of the causal effect between ART and 
preterm birth is in part due to the limitations in comparing findings across many observational 
studies employing a wide range of methodological approaches. New observational studies should 
consider enrolling larger numbers of preconceptional women to better estimate time of 
conception and ascertain a better estimate of the total number of pregnancies at risk. Analyses of 
data from observational cohorts should consider survival methods as an alternative to binary 
regression to more flexibly accommodate the realities of changing treatments in observational 
contexts, and to facilitate ease of interpreting findings within and across studies. Additional 
analysis options for observational pregnancy cohorts could also include target trial approaches,69 
which offer the opportunity to make clear causal claims in the absence of randomized control 
trial data.  Data collection for this analysis pre-dated the introduction of the integrase strand 
transfer inhibitors (INSTIs) class of drugs, but the methods we used in this paper would be 
particularly relevant as studies are now increasingly examining the effect of INSTIs on preterm 
birth risk compared to other ART regimens. In the absence of randomized evidence, it is 
important that researchers consider using methods like those demonstrated in this study to 
appropriately address the potential sources of bias common to observational studies of 




4.9 Tables and Figures 
Figure 4.1. Survival analysis framework detailing subject eligibility, exposure and outcome 
relative to gestational weeks for Aim 1.  
 
 
Figure 4.2. Consort diagram of pregnancies eligible for analysis from the Women and Infants 




Table 4.1. Baseline characteristics of 1067 singleton pregnancies from 932 women living with 
HIV enrolled between 1996 and 2005 in WITS.  
Baseline Characteristic N Value  [% or Mean (IQR)] 
Total Number of Women  932   
Pregnancies in the study from the same woman     
1 813 87.2% 
2 106 11.4% 
3+ 13 1.4% 
      
Race/Ethnicity      
White  91 8.5% 
Black 446 41.8% 
Hispanic 359 33.6% 
Other 21 2.0% 
Unknown 20 1.9% 
      
Total Number of Pregnancies  1067   
Maternal Age      
18-24 355 33.3% 
25-34 569 53.3% 
35-49 143 13.4% 
      
Baseline BMI 752 26.9  [23.2, 31.4] 
Missing  315 29.5% 
      
Baseline BMI     
Less than 19.8 29 2.7% 
19.8 - 26.0  302 28.3% 
Greater than 26.0 421 39.5% 
Missing  315 29.5% 
      
Substance Use During Pregnancy     
Cigarettes  329 30.8% 
    Missing  4 0.4% 
Alcohol 213 20.0% 
    Missing  3 0.3% 
Marijuana 117 11.0% 
    Missing  11 1.0% 
Hard Drugs 211 19.8% 
    Missing 3 0.3% 
      
Gestational Age at Study Entry  (Weeks) 1067 17 [12, 21] 
      
CD4 at Enrollment 897 425 [289, 605] 
Missing  170 15.9% 
      
Viral Load at Enrollment 798 2134 [0, 15000] 
Missing 269 25.2% 
      
Virally Suppressed at Enrollment (<400 copies/ml3)* 255 23.9% 
Missing 269 25.2% 
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 Baseline Characteristics (continued) N  Value  [% or Mean (IQR)] 
ART Regimen Status at Enrollment     
No Therapy  545 51.1% 
PI cART  232 21.7% 
NNRTI cART  32 3.0% 
ZDV Monotherapy  216 20.2% 
Other/Mixed Therapy 42 3.9% 
      
Observed gestational weeks by regimen (N = 22246)     
No Therapy  7210 32.4% 
PI cART  6778 30.5% 
NNRTI cART  940 4.2% 
ZDV Monotherapy  6010 27.0% 
Other/Mixed Regimen 1308 5.9% 
      
Switching Regimen During Pregnancy 311 29.1% 
      
HIV Transmitted to Child 21 2.0% 
Missing or Inconclusive  111 10.4% 
      
Pregnancy Outcome      
Live Birth  1048 98.2% 
Still Birth  13 1.2% 
Spontaneous Abortion  6 0.6% 
      
Gestational Age at Delivery  1067 38.0 [37.0, 39.0] 
      
Gestational Age at Delivery     
Term (>37 weeks)  875 82.0% 
Preterm (20 - 36 weeks)  192 18.0% 
Late Preterm (32 - 36)  146 13.7% 
Very Preterm (28 - 32)  23 2.2% 
Extremely Preterm (20 - 28)  23 2.2% 
      
Mode of Delivery      
Elective C-Section 266 24.9% 
Non-Elective C-Section  131 12.3% 
Assisted Vaginal Delivery  27 2.5% 
Spontaneous Vaginal Delivery  460 43.1% 
Vaginal Delivery (assisted status unknown)  10 0.9% 
C-Section (elective status unknown)  48 4.5% 
Delivery mode unknown  4 0.4% 
Missing  121 11.3% 







Table 4.2. Unweighted and weighted risks and risk differences for the effect of ART regimen on preterm delivery among 
pregnancies enrolled in WITS between 1996 and 2005 from women living with HIV (aged 15 to 45) accounting for time-varying 
exposure with bootstrapped 95% confidence intervals (N = 1067).   
  Unweighted   Weighted* 
  Births Censored Risk  95% CI  RD 95% CI    Risk  95% CI  RD 95% CI  
Preterm (<37 Weeks)                        
PI cART 62 6 0.16 (0.14, 0.19) 0. 0.   0.17 (0.14, 0.20) 0. 0. 
No Therapy 64 295 0.23 (0.19, 0.26) 0.06 (0.02, 0.10)   0.21 (0.17, 0.26) 0.05 (0.00, 0.10) 
NNRTI ART  2 0 0.05 (0.00, 0.10) -0.12 (-0.18, -0.06)   0.07 (-0.04, 0.18) -0.10 (-0.21, 0.02) 
ZDV Monotherapy 56 8 0.16 (0.14, 0.19) 0.00 (-0.03, 0.04)   0.20 (0.16, 0.24) 0.03 (-0.02, 0.08) 
                        
Very Preterm (<32 Weeks)                        
PI cART 9 5 0.02 (0.01, 0.03) 0. 0.   0.02 (0.01, 0.04) 0. 0. 
No Therapy 22 260 0.06 (0.04, 0.08) 0.04 (0.02, 0.06)   0.06 (0.03, 0.08) 0.03 (0.01, 0.06) 
NNRTI ART ** 0 0 0.00 (0.00, 0.00) NA NA   0.00 (0.00, 0.00) NA NA 
ZDV Monotherapy 14 6 0.04 (0.03, 0.05) 0.02 (0.00, 0.04)   0.05 (0.03, 0.07) 0.03 (0.01, 0.05) 
*Weighted risks and risk differences account for baseline viral load and maternal age.  




Figure 4.3. Unweighted and weighted risks and risk differences for the effect of ART regimen 
on (A) preterm delivery and (B) very preterm delivery among pregnancies accounting for time-
varying exposure.  Unweighted estimates are in lighter shades and weighted estimates are in 








Figure 4.4. Cumulative incidence curves for delivery among 
singleton pregnancies enrolled in WITS between 1996 and 
2005 from women living with HIV (aged 15 to 45) by time-
varying exposure (N = 1067). Dashed lines appear at 20 and 
37 weeks marking the preterm delivery period.   
Figure 4.5. Cumulative incidence curves for delivery among 
singleton pregnancies, weighted for baseline viral load and 
maternal age.  
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CHAPTER 5: AIM 2 - EXPLICITLY EMULATING A TARGET TRIAL USING 
OBSERVATIONAL DATA: AN APPLICATION TO THE EFFECT OF ART IN 
PREGNANCY ON PRETERM BIRTH AND LESSONS LEARNED 
5.1 Introduction 
Randomized controlled trials are considered the gold standard to address causal questions 
about the effect of exposures on outcomes.109 Often however, the ideal trial may not be feasible 
or ethical, particularly when the question involves human subjects. This is particularly the case 
when considering comparative effects among vulnerable populations, like pregnant women.110 
Groups are considered vulnerable when the ability to protect their interests and to provide 
informed consent is compromised in some way.111,112 Pregnant women are fully capable of doing 
both, but because they are also responsible for protecting the health and interests of a growing 
fetus which cannot actively offer consent, there is a more complex calculus when weighing the 
risks and benefits of participating in medical research.  
Medical research involving human subjects may be conducted in a variety of ways, 
broadly categorized as being either experimental and observational in design. The quintessential 
type of experimental design is the randomized controlled trial (RCT), where the investigator 
randomly assigns each study subject to receive an intervention and subsequently follows all 
subjects over a period of time to observe an outcome of interest.113  Among many other 
applications, this design is the standard in pharmaceutical research to establish the safety and 




With the first successful placebo-controlled RCT demonstrating the effect of 
azidothymidine (AZT) against HIV in 1987,114 the next three decades saw the introduction of 
over 25 antiretroviral drugs and drug combinations to market.115  However, conventionally 
vulnerable populations, including pregnant populations living with HIV, have historically been 
under-represented in RCTs studying HIV treatment.110,116  Ascertaining safety, teratogenicity, 
dosing and efficacy of ART drugs and regimens in pregnancy can therefore be challenging, and 
conducting an RCT including pregnant women living with HIV relies heavily on justifying true 
equipoise prior to randomizing treatment. More generally, RCTs can be prohibitively expensive 
and resource intensive; the costs and logistical burden of identifying study subjects, randomizing 
exposures, blinding investigators if applicable, documenting adverse events, coordinating 
additional safe-guards accommodating vulnerable populations, mitigating lost to follow up, etc. 
can be substantial.  These considerations pose an additional barrier to studying pregnant 
women.117  
 When RCTs are not feasible due to ethical and practical considerations, pregnant HIV 
populations are frequently studied using observational cohorts. In contrast to RCTs, the 
investigators do not directly intervene on activities or exposures of the study subjects.118 Rather, 
researchers observe a group of study subjects with varying levels of an exposure over time to 
examine the occurrence of one (or more) outcomes of interest.113  Pregnant women living with 
HIV are identified and followed over time; their exposures, outcomes and other details are 
recorded usually through a combination of medical chart abstraction and/or study questionnaires 
at regularly scheduled clinical visits. This design offers a workaround when ethical and practical 
considerations pose challenges, but as with any study, the success of observational cohort studies 
depends heavily on the specific and appropriate definition of the study population, exposure and 
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outcome, as well as valid and consistent measurement of important covariates and 
confounders.67,118 Not doing so means that the analysis and the resulting inferences will likely be 
limited.  
The observational studies exploring the effect of ART type on preterm birth among HIV-
positive pregnant women are limited in three primary ways. First, these studies are prone to 
selection bias.  For example, several observational studies conducted in Europe, the United 
States, and sub-Saharan Africa have reported that preconceptional ART use is associated with 
increased risk or odds of preterm birth.43,49,58–61 This finding lacks biological plausibility54,55 and 
is likely due to the systematic exclusion of women who initiate ART after delivery.51,56  Women 
initiating ART after delivery are often removed from the risk set (even if they experienced 
preterm birth) due to poorly defined inclusion criteria conditioning on exposure early in 
gestation, thereby biasing the study sample.51 One way to address this type of bias is to include 
all fetuses at risk of the outcome – independent of initiation timing – in estimating risk.62  By 
extension, cohort membership should be defined by exposure at baseline, however observational 
analyses of existing data often inadvertently violate this principle by using “future exposures” to 
define cohort membership at baseline, inducing both selection bias and possibly immortal 
person-time.63  Trials mitigate the possibility of this sort of bias;  the explicit, a priori definition 
of subject eligibility and the random assignment of exposure at the time of subject eligibility 
assessment help ensure that the exposure is independent from other factors.  
Second, the inferences derived from observational cohorts can be limited by the use of 
inappropriate analysis methods. Many studies examining HIV and preterm birth are prospective 
or retrospective cohort studies, which utilize binary regression methods to estimate risk or odds 
ratios. The use of binary regression itself need not be wrong; rather the method assumes that 
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exposure is time-fixed, but this assumption is rarely made explicit when researchers report and 
interpret the effect estimate for the reader.64 This is particularly relevant in pregnant populations 
when a woman can experience time in pregnancy being both exposed and unexposed to a 
treatment like ART, for example.119 Further, women enrolled in a cohort typically have different 
start times, dependent on pregnancy detection and timing of the first prenatal visit. (RCTs by 
comparison, are specifically designed to start all subjects at the same “time zero.”)69 The 
possibility of having unobserved time at the beginning of pregnancy opens the door to competing 
risks (like miscarriage) not being accounted for in the analysis, or again, immortal person-time 
bias.120  
Third, the effect estimates derived are not always useful to clinical decision-making. For 
example, logistic regression produces odds ratios. Odds ratios are very often reported in the 
literature but are hard to understand and interpret. Odds ratios are commonly understood and 
operationalized as risk ratios, even though odds tend to overestimate the true risk.64,65 If the 
outcome is considered rare (<10% prevalent in the study population), the risk ratio and odds ratio 
approximate each other. However, the margin of overestimation increases as the outcome 
becomes more common. This is problematic given that the prevalence of preterm birth is >10% 
among pregnant women living with HIV. This challenge may be addressed by simply choosing a 
different model to directly estimate risk, like log-binomial regression, or estimating weighted 
cumulative incidence curves using survival analysis.   
Another way to estimate effects using observational data is to emulate a target trial.67–70 
In the most literal sense, a target trial is a hypothetical RCT that we would wish to conduct under 
ideal circumstances. Thinking about studies in this way offers a useful heuristic to clarify the 
study design and the corresponding claims of effect we wish to make.67 When emulating a target 
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trial with observational data, the target trial is the RCT we would design with the variables 
contained within the observational dataset we intend on using, assuming of course that the 
dataset contains sufficient information on confounders to approximate baseline 
randomization.68,69 If the emulation is successful, the results would be comparable to results from 
the target trial, had it been conducted.  To be clear, the emulated target trial will essentially be a 
pragmatic trial, when treatments are compared under conditions in which they would usually be 
applied, to study subjects more representative of real world patient population.113 This is in 
contrast to a more classically designed RCT with stringent inclusion and exclusion criteria which 
produce results with high internal validity but may lack in its ability to generalize results to the 
patient population for whom the results were intended.113 Further description of pragmatic trials 
are available elsewhere.67,121,122  
The value in analyzing observational data using the target trial lens lies in the ability to 
approach causal inference explicitly, as opposed to the implicit (and perhaps informal) attempts 
at causal analyses using observational data.69 Doing so offers investigators a structured process 
for assessing observational studies and their ability to make causal claims.67,69  In this paper, we 
briefly discuss the specific mechanisms of designing a target trial;  then we go through a worked 
example of how to emulate a target trial using observational data from the Women and Infant 
Transmission Study to estimate the effect of ART on preterm birth; 1,3 and finally we discuss the 
quality of the emulated trial as per our worked example and lessons learned.  
5.2 Methods 
The specific components of a target trial and how to emulate it using observational data 
are described in detail by Hernán and Robins.67 We describe here how to appropriately define the 
eligibility criteria, determine the mechanics of treatment assignment and emulate randomization. 
The eligibility criteria for an emulated target trial analysis should be identical to that of the target 
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trial.67,69 Further, eligibility cannot be determined by events occurring after baseline for the same 
reason that in a true randomized trial setting, it would be impossible to include women into a 
study by conditioning on future events.  In an emulated trial setting, treatments are consistent 
with baseline characteristics and remain constant throughout the study to approach the intent-to-
treat principle.  Since randomization is a key component absent from observational study 
designs, we can either assume that exposure is unconditional, or we can assume that exposure is 
conditional on baseline characteristics and control for baseline covariates in the analysis to 
achieve comparability between treatment groups.67,69 For this study, we outlined the target trial 
components alongside our emulated target trial protocol in Table 5.1.  
The aim of the target trial (and by extension the emulated target trial) is to estimate the 
comparative causal effect of a newly initiated HIV treatment regimen at 20 weeks gestation on 
preterm birth among HIV-positive pregnant women. Women are eligible for randomization in 
the target trial if they are HIV-positive; their pregnancies survive to 20 weeks; are ART-naïve 
prior to 20 weeks of pregnancy; and have no history of alcohol or drug abuse, AIDS-defining 
illness, Type I/II diabetes; genetic or fetal abnormalities, or are taking medication that is 
contraindicated with study exposures. Women are randomized at 20 weeks to either PI cART, 
NNRTI cART, ZDV monotherapy and No Therapy.  
5.3 Study Population 
The emulated target trial analysis uses data from WITS collected between 1990 and 2005. 
The WITS was a prospective, interval cohort of pregnant women living with HIV. Women were 
allowed to enroll at any time during pregnancy and were followed until the end of pregnancy. 
Exposure and covariate data were collected at each study visit using standardized study 
questionnaires, as well as through retrospective medical record abstraction. There was no lost to 
follow up or right-censoring. Further details about this cohort are available elsewhere.1,2  In our 
 
54 
emulated target trial, we included women from WITS who were unexposed to ART at 
conception and were pregnant with a single fetus surviving to 20 weeks.  
In contrast to the target trial, inclusion to the emulated trial was not dependent on prior 
alcohol abuse, drug abuse, history of diabetes, or history of hypertension. These will be 
accounted for in the analysis. If a woman contributed multiple pregnancies to the WITS cohort, 
we included only her first pregnancy into the analysis population. Women not exposed to one of 
the four treatment strategies at their first exposure were also excluded.  Additionally, women 
were eligible for “treatment assignment” if they enrolled into WITS between 18 and 22 weeks 
gestation (Figure 1). This differs from the described target trial since both eligibility assessment 
and randomization occur at 20 weeks, however we consider the window of 18 to 22 weeks to be 
narrow enough to still be reasonably consistent with the target trial protocol. Further detail on 
exposure definition is in a following section.     
5.4 Outcome Classification 
Pregnancies ending in live birth (hereafter referred to as “birth” or “delivery”) as a result 
of spontaneous labor onset between 20 weeks and 36 6/7 weeks were considered preterm. A 
secondary outcome was considered combining preterm births and all stillbirths. This secondary 
outcome was of interest because both preterm birth and stillbirth can be caused by ART 
exposure.49,79  Very preterm (20 – 32 weeks) and extremely preterm (20 – 28 weeks) were not 
considered in this analysis due to the rare occurrence of these events in our data.  
5.5 Exposure and Confounder Classification  
Exposures considered in this analysis are from drug classes prescribed at the time of data 
collection, namely PIs; nucleoside reverse transcriptase inhibitors (NRTIs); and non-nucleoside 
reverse transcriptase inhibitors (NNRTIs). Exposure categories for the emulated target trial were 
defined as no therapy, Zidovudine (ZDV) monotherapy; PI-based cART; and NNRTI-based 
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cART. If ZDV monotherapy was prescribed concurrently with cART, the more suppressive, 
combination therapy was prioritized for exposure categorization.22  Women starting on any 
combination not falling into these categories were excluded from the analysis.  Women in the 
emulated target trial analysis were prescribed an exposure corresponding to the time of 
enrollment (occurring between 18 and 22 weeks gestation).  We were unable to confirm if 
women were ART-naïve at conception due to incomplete data on treatment history and timing of 
HIV diagnosis, but we assumed that if women were unexposed at enrollment or data from 
medical record abstraction indicated that women initiated treatment in pregnancy shortly prior to 
enrollment, they were likely unexposed as conception.   
Baseline information about each pregnancy was collected at the WITS enrollment visit 
through standardized enrollment questionnaires. Race/ethnicity was classified into four racial 
categories (American Indian or Alaskan Native, Asian or Pacific Islander, Black, and White) and 
two ethnic categories (Hispanic origin, and Not of Hispanic origin) as per the 1996 U.S. Census 
Bureau conventions. Racial and ethnic categories were combined into a single race/ethnicity 
category in the WITS as White, Black, Hispanic and other (including Native American/Alaskan 
Native and Asian/Pacific Islander).  BMI was calculated using weight and height at enrollment 
visit and categorized into the following standardized categories from the study period:123 <19.8, 
19.8 to 26.0; and >26.0. The following covariates were all coded dichotomously as yes/no: pre-
pregnancy diabetes;  pre-pregnancy hypertension; pre-pregnancy diagnosis of an AIDS-defining 
illness;  and reported use of cigarettes, marijuana, crack/cocaine, heroin or alcohol at the WITS 
enrollment visit.  WITS follow-up spanned two decades with evolving HIV treatment guidelines; 
treatment era was categorized as follows: 1990 to 1994 when there was no standard HIV 
treatment; 1994 to 1996 when ZDV monotherapy was the standard of care in pregnancy; and 
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1996 to 2005 when suppressive, combination therapy was introduced and scaled up (also known 
as highly active ART or HAART).  Baseline viral load measurements, CD4 count and maternal 
age were recorded at enrollment into the WITS  and modeled as restricted quadratic splines with 
four equal knots.100   
5.6 Statistical Methods 
Maternal characteristics were summarized, with stratification according to ART regimen 
at baseline. We emulated randomization of the target trial in two ways: first by assuming that 
treatment assignment was unconditional, and second that treatment assignment was conditional 
on measured baseline covariates. For this second approach, we used the minimally sufficient set 
of baseline covariates based on a causal diagram to estimate causal effects (Appendix Figure 
A.2).  We calculated the crude risk of preterm birth by regimen and used modified Poisson 
models with robust variance estimators to estimate risk ratios (RR) and 95% confidence 
intervals.74  Risk ratios were estimated for the effect of baseline ART on preterm birth, 
comparing each exposure group to PI cART as the reference.  
We conducted an identical analysis to examine how sensitive our emulated target trial 
estimates were to widening the enrollment window from 18 to 22 weeks to 12 to 28 weeks. This 
sensitivity analysis included women enrolling at any time in the second trimester of pregnancy 
and was the prescribed treatment was based on that recorded at the time of enrollment.  
5.7 Missing Data 
Missing values were dealt with using multiple imputation (MI).75,124 While we had 
complete exposure and outcome data, there were several baseline covariates we wished to 
include in our multivariate model which had missing values.  We included variables in the MI 
models that were used in the analytic models for the main effect, as well as auxiliary variables to 
improve the overall fit of the imputation model.76 We then performed multiple imputation by 
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chained equations, generating 30 imputed datasets for each analysis. We then ran the analysis 
multivariate model on each imputed dataset and pooled the resulting parameters using Rubin’s 
Rule to derive the adjusted risk ratios and 95% confidence intervals.124  
5.8 Results 
Of the 3297 pregnancies in WITS, 2922 pregnancies were excluded for enrolling prior to 
18 weeks or after 22 weeks; 18 pregnancies were excluded for being either multiple gestation, 
ending prior to 20 weeks or being from the same woman; 39 were excluded for preconceptional 
exposure to ART and 58 were excluded for starting on non-study therapy.   The final analysis 
sample was 260 (Figure 5.2). Given our strict definition of eligibility as per the stated target trial, 
the resulting study sample is considerably smaller than the WITS cohort. As expected, the 
distribution of ART regimens corresponded to the treatment era of the pregnancy. Only 
pregnancies occurring after 1996 were subject to PI exposure since this regimen was unavailable 
prior to 1996, with very few pregnancies exposed to NNRTI cART overall.  Values were missing 
for baseline viral load, BMI and history of diabetes and hypertension. Maternal characteristics 
stratified by exposure group and the corresponding proportion of missing values are presented in 
Table 5.2. 
Based on our causal diagram, baseline covariates important to emulating randomization 
included race and ethnicity, maternal age, baseline BMI, history of substance use (including 
cigarettes, alcohol, marijuana and hard drugs), baseline viral load, pre-pregnancy AIDS-defining 
illness, study site and treatment era. From these covariates we identified a minimally sufficient 
adjustment set to achieve a parsimonious multivariate model, which included baseline viral load, 
pre-pregnancy AIDS-defining illness, treatment era, study site and maternal age.  Study site was 
unavailable in our dataset. We imputed missing values of baseline viral load using the analytic 
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model variables and the following auxiliary variables: CD4 count, pre-pregnancy substance use 
in pregnancy, and race/ethnicity.  
Assuming randomization in our emulated target trial to be unconditional, pregnancies 
started on No Therapy at baseline had a higher risk of preterm birth when compared to PI cART, 
though not significant [RR: 1.12, 95% CI (0.69, 1.81)] (Table 5.3). Comparing the other study 
exposures to PI cART yielded similarly insignificant results, though surprisingly, the risk ratio 
estimate for ZDV monotherapy suggested protection when compared to PI cART. We did not 
see materially different results when we assumed that randomization was conditional on baseline 
covariates. The multivariate analysis further suggested that women exposed to No Therapy 
would have a lower risk of preterm birth than those starting on PI cART [RR: 0.79; 95% CI: 
(0.42, 1.46)].  The sensitivity analysis included considerably more women by allowing 
enrollment throughout the second trimester. (N = 972) (Table D.1) Even so, the analysis did not 
offer results that differed from the primary emulated target trial, though we gained precision in 
our risk ratio estimates (Table D.2). Effect estimates examining the effect of ART on the 
secondary outcome (live still births combined with all stillbirths) were not materially different 
than that from the primary analysis and are not reported.  
5.9 Discussion 
In this analysis, we aimed to demonstrate how a target trial may be emulated using 
observational data. We expected the results of the emulated target trial to yield interpretable risk 
ratios showing PI cART preventing preterm birth when compared to no therapy and 
monotherapy, and that there would be no material difference between preterm birth risk between 
pregnancies starting on PI cART and NNRTI cART.  After adjusting for identified baseline 
covariates present in the dataset, preterm birth risk for women starting pregnancy on PI cART at 
20 weeks was higher when compared to all other exposures (though all risk ratios were 
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statistically insignificant.) This finding is contrary to what has been scientifically established in 
the ART literature; monotherapy is a decisively inferior treatment option compared to 
combination ART regimens, in relation to both preventing vertical HIV transmission and in 
preventing preterm birth.37,125 One of the likely reasons for these surprising results is that our 
sample size was quite small to detect any meaningful effect between exposures given our strict 
target trial emulation eligibility criteria. Additionally, our dataset had a significant amount of 
missing data and measurement error, likely contributing to uncontrolled confounding at baseline 
and biasing our results.  
Bias is essentially a missing data problem.126 For this analysis, the nature of missingness 
may be divided into two groups.  First, missing data in the form of measurement error is 
generally expected from an observational study setting. Measurement error may be introduced at 
virtually all stages of data collection and data entry, including but not limited to: identifying 
appropriate study participants; relying on participant recall for key data (including treatment 
exposures); ensuring the paper forms used for data collection are legible; following participants 
faithfully throughout follow-up; ensuring the reliable collection of all study variables; promoting 
consistency of study management throughout the observation time; entering the data into a 
database without error; etc.127 The aforementioned list highlights the expected risks of an 
observational study which may be addressed, at least in part, through mitigation strategies 
throughout the study and analysis process. Even so, implementing a large, multi-site 
observational study like the WITS, spanning more than two decades is immensely challenging 
and we usually expect some presence of measurement error because of these challenges. It is 
particularly clear from the extent of missing baseline viral load data for example, that data 
quality was quite low, making the WITS a poor candidate for target trial emulation.  
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The second sort of missing data is a bit more specific to this analysis. In order to create a 
dataset for public use, the study team removed or altered key variables from the original dataset 
to ensure the confidentiality of the study participants. (The original dataset was destroyed as per 
NIH requirements.)  This means that in our analysis, we were unable to account for variation by 
study site which would have been a baseline covariate to adjust for. We were also unable to 
consider other important baseline characteristics like parity and gravidity; and timing of exposure 
and gestational age in precise calendar time. Missingness of this kind is particularly problematic 
when pursing causal claims because we can no longer make safe assumptions regarding the 
absence of unmeasured confounding, nor can we assume – even in expectation – that the causal 
criteria are met.128  
The hallmark strength of an RCT is that in principle, randomization distributes measured 
and unmeasured confounders between the exposure groups of interest such that a counterfactual 
population is approximated to facilitate a causal contrast. Recall that to usefully emulate a target 
trial, randomization is approached through controlling for important covariates at baseline and 
then preserving this “randomization” through an intention-to-treat analysis allowing for unbiased 
causal effect estimates.67 We were ultimately unsuccessful because we were unable to emulate 
randomization reliably, thus yielding logically impossible results.  Applying the target trial 
approach alone does not facilitate valid results.  
The target trial approach can certainly be useful when the underlying observational 
dataset contains the necessary variables measured reasonably to simulate the conditions of a 
randomized controlled trial and has enough subjects across the exposures of interest. Future 
observational cohorts of ART exposures and their effect on adverse birth outcomes should 
consider this method to facilitate causal claims of risk. This approach would be particularly 
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feasible using large administrative datasets like Medicare or payor datasets, where achieving 
power would be less of barrier. Planning an observational cohort study knowing that the analysis 
method relies heavily on appropriate and complete measurement will set the stage for making 
powerful causal claims in the observational context. This is particularly relevant as new 
formulations of ART are coming on the market and vulnerable populations, like pregnant 
women, will need to be considered, not just for the prevention of vertical transmission, but also 






5.10 Tables and Figures 
Table 5.1. Study protocol summaries for the proposed target trial and the related emulated target trial to examine the causal effect of 
ART on preterm birth in the WITS dataset, 1990 – 2005. 
Component Target Trial Emulated trial using WITS Observational Data 
Aim  To estimate the comparative causal effect of a newly initiated 
HIV treatment regimen at 20 weeks gestation on preterm birth 
among HIV-positive pregnant women.  
Same.  
Eligibility  Women are eligible for randomization in the target trial if they 
are HIV-positive; their pregnancies survive to 20 weeks; are 
ART-naïve prior to 20 weeks of pregnancy; and have no history 
of alcohol or drug abuse, AIDS-defining illness, Type I/II 
diabetes; genetic or fetal abnormalities, or are taking medication 
that is contraindicated with study exposures.  
Same as Target Trial except for the following:  
1. Women are eligible if they enrolled into WITS between 18 and 22 
weeks gestation.  
2. Women should be unexposed to ART at conception 
3. Inclusion will not be dependent on alcohol/drug use, diabetes or 
hypertension (these will be controlled for in analysis)  
4. Pregnancies not exposed to one of the four treatment strategies as 
their first exposure will be excluded. 
Treatment Strategies  PI cART, NNRTI cART, ZDV monotherapy and No Therapy Same.  
Treatment 
Assignment  
Women are randomly assigned to one of four treatment 
strategies at 20 weeks gestation 
Women are assigned the exposure recorded at their enrollment visit 
between 18 and 22 weeks.  
 
Randomization is emulated via adjustment for baseline covariates 
Follow-up  Follow-up starts at treatment assignment at 20 weeks and ends 
at delivery, death or loss to follow-up. All enrolled pregnancies 
will be followed until delivery.  
Follow-up starts at enrollment and ends at delivery. There is no right 
censoring, death or lost-to-follow up in these data.  
Outcome  Outcome 1: spontaneous live births occurring prior to 37 weeks 
gestation 
Outcome 2: spontaneous live births occurring prior to 37 weeks 
gestation and all stillbirths 
Same 
Causal Contrast  Intention-to-treat effect, i.e., the effect of being assigned to No 
Therapy, ZDV Monotherapy or NNRTI cART compared to PI 





Statistical Analysis  Intention-to treat analysis. Same  
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Table 5.2. Baseline and pregnancy characteristics of singleton pregnancies surviving past 20 
weeks from eligible women enrolled in WITS between 1990 and 2005 (N = 260).  
  PI cART No Therapy ZDV NNRTI cART   
Characteristics  102 111 37 10   
  Column Percentages (%) 
Race/Ethnicity  
    
  
White  6.9 9.9 10.8 10.0   
Black 44.1 51.4 46.0 70.0   
Hispanic/Latina 48.0 30.6 40.5 20.0   
Other 0.0 0.9 0.0 0.0   
Unknown 0.0 5.4 0.0 0.0   
Missing 1.0 1.8 2.7 0.0   
      
Maternal Age  
    
  
18-24 33.3 37.8 48.7 30.0   
25-34 52.9 51.4 43.2 60.0   
35-49 13.7 10.8 8.1 10.0   
  
    
  
Treatment Era 
    
  
<1994 2.0 57.7 21.6 0.0   
1994 to 1996  11.8 15.3 43.2 20.0   
>1996 86.3 27.0 35.1 80.0   
  
    
  
Baseline BMI* 
    
  
Less than 19.8 1.0 1.8 2.7 0.0   
19.8 - 26.0  34.3 27.9 16.2 30.0   
Greater than 26.0 33.3 31.5 18.9 50.0   
Missing  0.8 38.7 62.2 20.0   
  
    
  
History Substance Use 
    
  
Cigarettes  24.5 40.5 29.7 30.0   
Missing  0.0 0.0 0.0 0.0   
  
    
  
Alcohol 20.6 41.4 46.0 20.0   
Missing  0.0 0.0 0.0 0.0   
  
    
  
Marijuana 5.9 18.0 0.0 20.0   
Missing  1.0 0.0 0.0 0.0   
  
    
  
Hard Drugs 19.6 33.3 21.6 20.0   
Missing 30.4 3.6 0.0 20.0   
  
    
  
History Chronic Disease 
    
  
Hypertension 3.9 6.3 5.4 10.0   
Missing  30.4 3.6 0.0 20.0   
  
    
  
Diabetes 2.0 2.7 0.0 0.0   





  PI cART No Therapy ZDV NNRTI cART   
Characteristics  102 111 37 10   
Gestational Age at WITS enrollment in Weeks 
   
  
Mean (IQR) 20 (19, 21) 20 (19, 21) 20 (19, 21) 20 (19, 21)   
  
    
  
CD4 at Enrollment 
    
  
<200 10.8 7.2 10.8 10.0   
201-349 20.6 12.6 13.5 10.0   
350-500 21.6 15.3 5.4 20.0   
>500 21.6 27.9 13.5 30.0   
Missing 25.5 36.9 56.8 30.0   
  
    
  
Viral Load at Enrollment (copies/ml3) 
    
  
     <400** 20.6 1.8 8.1 30.0   
     401-10,000 26.5 12.6 10.8 20.0   
     >10,000 10.8 15.3 13.5 20.0   
     Missing 42.2 70.3 67.6 30.0   
  
    
  
History of AIDS-defining Illness 4.9 6.3 16.2 0.0   
  
    
  
Pregnancy Outcome  
    
  
Live Birth  98.0 91.0 97.3 100.0   
Still Birth  2.0 2.7 0.0 0.0   
Therapeutic Abortion  0.0 1.8 0.0 0.0   
Spontaneous Abortion  0.0 4.5 2.7 0.0   
  
    
  
HIV Transmitted to Child 2.9 12.6 5.4 10.0   
     Missing  3.9 9.9 8.1 0.0   
  
    
  
Gestational Age at Delivery 
    
  
Term (≥37 weeks)  77.5 74.8 81.0 90.0   
Preterm (20 - 37 weeks)  22.6 25.2 18.9 10.0   
Very Preterm (20 - 32 weeks)  3.9 11.7 2.7 10.0   
Extremely Preterm (20 - 28 weeks)  0.0 9.9 2.7 0.0   
  
    
  
Mode of Delivery  
    
  
Elective C-Section 25.5 11.7 5.4 10.0   
Non-Elective C-Section  12.8 7.2 18.9 30.0   
Assisted Vaginal Delivery  4.9 3.6 0.0 20.0   
Spontaneous Vaginal Delivery  44.1 61.3 62.2 30.0   
Vaginal Delivery (assisted status unknown)  0.0 1.8 0.0 0.0   
C-Section (elective status unknown)  3.9 3.6 5.4 10.0   
Missing  8.8 10.8 8.1 0.0   
*BMI categorization is based on standards relevant at the time of data collection.37      








Table 5.3. Risks and Risk Ratios of preterm birth by baseline exposure among women eligible for the emulated target trial analysis in 
the WITS cohort with 95% confidence intervals, assuming that randomization is unconditional (Analysis 1) and that randomization is 
conditional on baseline covariates (Analysis 2). 
      Analysis 1 
 
Analysis 2**   
  Number of Events Risk (%) RR 95% CI*   RR 95% CI    
Emulated Trial  N = 260               
PI cART 23 22.6 1.     1.     
No Therapy 28 25.2 1.12 (0.69, 1.81)   0.79 (0.42, 1.46)    
ZDV Monotherapy 7 18.9 0.84 (0.39, 1.79)   0.74 (0.32, 1.72)   
NNRTI cART 1 10.0 0.44 (0.07, 2.9)    0.50 (0.07, 3.4)    
**Model adjusted for the following minimally sufficient baseline covariates to emulate baseline randomization: baseline viral load, pre-




CHAPTER 6: DISCUSSION 
6.1 Overview 
Understanding the safety and efficacy of HIV treatment in pregnant populations is of 
urgent importance given the potential adverse effects on pregnancy and birth. Reconciling the 
confusion around the true effect of ART on preterm birth continues to be a challenge since some 
studies suggest differential harm, particularly implicating PI cART 43,48,81–83 while other studies 
show no difference in protection among suppressive regimens. 57,84,85  Reconciling these 
conflicting findings.43,48,81–83 Having as many valid analysis approaches as possible in the toolkit 
is essential to making sense of possible harms and benefits of ART, particularly during 
pregnancy. Our study reexamined the effect of PI cART on preterm birth by illustrating the use 
of alternative epidemiologic methods.  
For the first aim, we departed from the use of binary regression methods since they do 
not easily accommodate time-varying exposure. Reanalyzing the WITS data to estimate preterm 
birth risk utilizing survival methods, we hypothesized that the effect of PI ART on preterm birth 
would not be different than that among pregnancies exposed to other combination therapies.  For 
the second aim, we demonstrated the use of an analysis approach perhaps more appropriately 
using binary methods to understand the effect of ART on preterm birth to make causal claims. 
We hypothesized that the effect of PI ART on preterm birth derived from the emulated target 
trial would not be different than that among pregnancies exposed to other combination therapies, 




First, the use of survival methods is certainly not novel in pregnancy studies nor is it new 
in HIV studies, however we wanted to demonstrate its value in the context of HIV and 
pregnancy since this approach has not yet been fully embraced as a prioritized analysis method 
when the effect of treatment is studied in HIV populations. By estimating risks and risk 
differences, we were able to offer interpretable results that could more easily be applied to 
clinical practice and policy. Further, our analysis showed that by using survival methods, we 
were able to examine risk of preterm birth over the entirety of gestation, and not just at the 
conventional cut-points. This method also accounts for the realities of observational cohorts like 
exposures changing during pregnancy, late entry and competing risks.  
Second, ours is the first study to use an emulated target trial approach to facilitate causal 
claims reexamining the effect of ART on preterm birth.  It is difficult to study pregnancy in a 
randomized context given the ethical concerns of exposing a fetus to exposures with unknown 
effects. Because of the this, emulating a target trial offers a compelling way to approach an RCT 
environment while utilizing data from an observational cohort. Employing this method does not 
dispense with the usual limitations of observational studies; however it does mitigate the 
analysis-induced pitfalls often found in the literature like selection bias and immortal person-
time bias. The value of analyzing observational data using the target trial lens lies in the ability to 
approach causal inference explicitly.  
6.3 Limitations 
There were several limitations to note when considering the conclusions of this study in 
their entirety, primarily having to do with the quality of the data we used for both aims.  First, we 
used data from an observational cohort that started enrolling women almost 40 years ago and 
ended 15 years ago. HIV treatments and populations at risk have evolved significantly since 
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then, so the actual findings derived from our study are not clinically relevant in the present. Even 
though PIs are still utilized in sub-Saharan Africa, they are mostly considered as second line 
treatment, after virologic failure of first line ART.129  Additionally, the introduction of integrase 
inhibitors in 2012 and the scaling up of this drug class since then has shifted focus away from the 
ART regimens that were prominent in the 1990s and early 2000s.130 Even so, we hope that by 
demonstrating the use of appropriate methods in the HIV and pregnancy context, we can derive 
better inferences on the effect of new ART drug classes in pregnancy.   
A related limitation is that the findings from this study may not be entirely generalizable 
to the U.S. population of pregnant women living with HIV today. The use of drugs and alcohol 
in pregnancy has significantly reduced among women living with HIV compared to the time at 
which these data were collected.131 Additionally, people are risk of HIV are more frequently 
tested and linked to care given the expansion of universal test and treat programs in the United 
States.132 This means that a higher proportion of women would have initiated ART prior to 
conception. In contrast, our analysis is limited to pregnancies who started treatment after 
enrollment. We were unable to reliably identify women who initiated preconceptionally due to 
the limitations associated with exposure timing.  
Third, the WITS data are vulnerable to missing data and measurement error given that the 
study spanned more than 20 years of observation. Study protocols were updated, and several 
study sites were included and removed over this period. Data quality concerns are generally 
expected from an observational study setting since error may be introduced at virtually all stages 
of data collection and data entry, including but not limited to: identifying appropriate study 
participants; relying on participant recall for key data (including treatment exposures); ensuring 
the paper forms used for data collection are legible; following participants faithfully throughout 
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follow-up; ensuring the reliable collection of all study variables; promoting consistency of study 
management throughout the observation time; entering the data into a database without error; etc. 
Even so, accounting for this level of variably is challenging when the analysis dataset lacks the 
sufficient variables to fully describe this sort of variation.  
The study team removed or altered key variables from the original dataset to ensure the 
confidentiality of the study participants in order to create a dataset for public use. (The original 
dataset was destroyed as per NIH requirements.)  This meant that in our analysis, we were unable 
to understand the distribution of the removed variables and whether they would have been 
identified as important confounders or modifiers. This was challenging because we can no longer 
(comfortably) make the conventional analysis assumptions regarding the absence of unmeasured 
confounding, nor can we assume – even in expectation – that any the causal criteria are met. This 
was particularly important in Aim 2 when we sought to emulate a target trial.  Randomization 
was approached through controlling for important covariates at baseline and then preserving this 
“randomization” through an intent to treat analysis allowing for unbiased effect estimates.  The 
absence or unreliability of key variables prevented us from deriving reasonable inferences.  Our 
study demonstrated however that unless we have complete and reliable measurement of key 
covariates and confounders, emulating a target trial will be unsuccessful.  
Finally, timing of exposure in pregnancy was subject to patient recall in combination with 
medical record abstraction. It was unclear from the dataset whether the exposure start and stop 
times were derived from medical records or patient recall; because of this, we had to assume that 
the data were accurate, irrespective of source. If dates were missing, assumptions were made to 
ensure that the field was not coded as missing. The data cleaning was conducted by the study 
team so were blinded to the decision-making that was not detailed in the study documentation. 
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Because these challenges are in part expected when analyzing observational data, mitigation 
strategies may be used in both the study implementation and analysis. That said, it was difficult 
for us to know to what extent such measures were successful in our analysis.   
6.4 Conclusion  
 In conclusion, our study demonstrates the use of alternative methods through a worked 
example, for other researchers to consider when seeing to understand the relationship between 
ART and preterm birth. Our first aim examined the relationship of ART regimen on preterm 
birth using survival analysis to appropriately characterize changing exposure over the entire 
duration of pregnancy in the WITS population. Conventional analyses in the literature tend to 
categorize ART exposures as time-fixed in order to use binary analysis methods, and are often 
subject to selection bias or immortal time bias. Our study differed from these analyses by 
estimating risks and risk differences using the complement of the Kaplan-Meier estimator, 
accommodating time-varying exposure; and by prioritizing causal theory and substantive 
knowledge when considering covariate adjustment. Estimating risks and risk differences using 
survival analysis should be considered as an alternative to regression in an effort to harmonize 
methods across the field of study, particularly since the effect of new ART drugs in pregnancy 
are a priority.  
For our second aim, we demonstrated how to emulate a target trial for facilitate making 
causal claims about the effect of ART on preterm birth using observational cohort data. In doing 
so, we also highlighted the qualities required in the observational dataset to conduct the analysis 
successfully. For successful trial emulation, the “time zero” needs to be correctly specified and 
the observational data set needs to have sufficient information on confounders to emulate 
randomization. Using the WITS was ultimately a poor choice to illustrate the merits of this 
approach. Even so, our second aim offers an alternative way to analyze observational data with 
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the trial is not feasible, particularly given the challenges in conducting RCTs with pregnant 
women.  
Understanding the safety and efficacy of HIV treatment in pregnant populations is of 
urgent importance, given the constant introduction of new therapies. Designing cohort studies 
planning for the use of the analyses methods presented in this study will undoubtedly support 
appropriate and complete measurement of key variables, and will set the stage for making 
powerful causal claims in the observational context.  Studying pregnant populations is 
challenging given the practical and ethical concerns. We urge researchers in this field to consider 
the methods presented in this study to facilitate causal claims of risk and to promote decisive 
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APPENDIX B: SUPPLEMENTAL DESCRIPTION OF EXPOSURES  
Table B.1. Description of study exposures clarifying exposure definition and drugs comprising combination therapies.  
Study Exposure Categorization  Description  Regimen  
    Name, Abbreviation (FDA Approval Year)  
    Base Drugs    Backbone Drugs** 
Protease Inhibitor Combination ART  
(PI cART)   
Combination of 3 or more drugs 
containing PIs and NRTIs 
 
(sometimes given concurrently with 
ZDV monotherapy as per pregnancy 
treatment recommendations) 
Saquinovir, SQV (1995) 
Ritonovir, RTV (1996)* 
Lopinavir, LPV (2000) 
Atazanavir, ATZ (2003) 
+ 
  Zidovudine, ZDV (1987) 
  Didanosine, ddT (1991) 
  Lamivudine, 3TC (1995) 
  Abacavir, ABC (1998) 
  Tenofovir, TDF (2001) 
  Emtricitabine, FTC (2003)  Non-nucleoside Reverse Transcriptase 
Inhibitor Combination ART  
(NNRTI cART)  
Combination of 3 or more drugs 
containing NNRTIs and NRTIs 
 
(sometimes given concurrently with 
ZDV monotherapy as per pregnancy 
treatment recommendations) 
Nevirapine, NVP (1996) 
Efavirenz, EFV (1998) 
Mixed Therapies (effects not reported)  
Combination of 2 or more drugs 
including PIs and NNRTIs 
  
    
Zidovudine Monotherapy  ZDV only  Zidovudine, ZDV (1987)     
No Therapy  Unexposed to HIV treatment        
*In 2001, boosting with RTV was recommended for all PIs.       







APPENDIX C: AIM 1 - SUPPLEMENTAL TABLES AND FIGURES 
Figure C.1. Histogram showing the distribution of gestational 
age at delivery among singleton pregnancies enrolled in WITS 
between 1996 and 2005 from women living with HIV (aged 
15 to 45).  
Figure C.2. Cumulative incidence curve for delivery among 
singleton pregnancies enrolled in WITS between 1996 and 
2005 from women living with HIV (aged 15 to 45). Dashed 





Table C.1. Weighted risks and risk differences for the effect of ART regimen on preterm 
delivery among women enrolled in WITS between 1996 and 2005 from women living with HIV 
(aged 15 to 45) with bootstrapped 95% confidence intervals (N = 932).  
Risk (%) 95% CI RD 95% CI 
Preterm (<37 Weeks) 
PI cART 0.15 (0.13, 0.18) 0 0
No Therapy 0.23 (0.20, 0.26) -0.07 (-0.11, -0.03)
NNRTI ART 0.05 (0.00, 0.10) 0.10 (0.05, 0.16)
ZDV Monotherapy 0.16 (0.13, 0.19) -0.01 (-0.04, 0.03)




APPENDIX D: AIM 2 - SENSITIVITY ANALYSIS 
Table D.1. Selected baseline and pregnancy characteristics of singleton pregnancies surviving 
past 20 weeks from eligible women enrolling between 12 and 28 weeks (2nd trimester) in wits 
between 1990 and 2005 (n = 972). 
  PI cART  No Therapy  ZDV  NNRTI cART    
Characteristics  292 491 146 43   
  Column Percentages (%) 
Race/Ethnicity            
White  7.9 10.8 11.0 11.63   
Black 44.2 49.9 43.8 69.77   
Hispanic/Latina 44.9 33.2 39.7 16.28   
Other 2.4 4.7 4.2 0.00   
Unknown 1.7 1.4 1.4 2.33   
            
Maternal Age            
18-24 36.6 37.3 43.2 39.5   
25-34 52.4 53.0 45.9 44.2   
35-49 11.0 9.8 11.0 16.3   
            
Treatment Era           
<1994 1.7 54.6 18.5 0.0   
1994 to 1996  9.9 21.2 43.8 16.3   
>1996 88.4 24.2 37.7 83.7   
            
Baseline BMI*           
Less than 19.8 3.8 2.4 1.4 4.7   
19.8 - 26.0  32.2 38.1 33.6 30.2   
Greater than 26.0 37.7 35.9 31.5 46.5   
Missing  26.4 23.0 63.0 33.6   
            
History Substance Use           
Cigarettes  29.5 45.2 37.7 30.2   
Missing  0.0 0.0 0.0 0.0   
            
Alcohol 25.7 47.7 38.4 23.3   
Missing  0.0 0.0 0.0 0.0   
            
Marijuana 9.3 17.9 14.4 14.0   
Missing  1.7 0.0 0.0 0.0   
            
Hard Drugs 17.8 39.7 28.8 23.3   
Missing 0.0 0.0 0.0 0.0   
            
History Chronic Disease           
Hypertension 4.5 7.5 11.0 4.7   
Missing  27.7 3.3 1.4 32.6   
            
Diabetes 2.1 1.8 2.7 0.0   
Missing  27.4 19.6 3.4 32.6   
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  PI cART  No Therapy  ZDV  NNRTI cART    
Characteristics (continued) 292 491 146 43   
     
Gestational Age at WITS enrollment in Weeks         
Mean (IQR) 19 (16, 22) 22(18, 26) 18 (15, 23)  19 (16, 23)    
            
CD4 at Enrollment           
<200 15.8 20.4 25.3 16.3   
201-349 9.6 10.2 8.9 4.7   
350-500 20.6 14.1 11.0 25.6   
>500 20.9 18.1 21.2 18.6   
Missing 33.2 37.3 33.6 34.9   
            
Viral Load at Enrollment (copies/ml3)           
<400** 24.0 5.5 12.3 34.9   
401-10,000 26.0 15.9 26.0 18.6   
>10,000 20.2 13.6 15.1 18.6   
Missing 29.8 65.0 46.6 27.9   
            
History of AIDS-defining Illness 4.8 4.3 7.5 0.0   
            
Pregnancy Outcome            
Live Birth  98.0 94.0 98.0 100.0   
Still Birth  1.4 4.0 1.4 0.0   
Therapeutic Abortion  0.3 0.4 0.0 0.0   
Spontaneous Abortion  0.3 1.6 0.7 0.0   
            
HIV Transmitted to Child 1.7 11.6 5.5 2.3   
Missing  3.1 4.5 5.5 0.0   
            
Gestational Age at Delivery           
Term (≥37 weeks)  81.2 77.8 80.1 90.7   
Preterm (20 - 37 weeks)  18.8 22.2 19.9 9.3   
Very Preterm (20 - 32 weeks)  3.4 6.9 6.2 4.7   
Extremely Preterm (20 - 28 weeks)  1.7 4.28 4.11 0   
            
Mode of Delivery            
Elective C-Section 24.32 8.76 8.9 20.93   
Non-Elective C-Section  12.33 12.22 15.07 9.3   
Assisted Vaginal Delivery  3.42 4.48 4.79 4.65   
Spontaneous Vaginal Delivery  43.15 61.3 56.16 60.47   
Vaginal Delivery (assisted status unknown)  1.37 3.05 2.05 0   
C-Section (elective status unknown)  5.14 1.83 2.05 2.33   
Missing  10.27 8.35 10.95 2.33   
*BMI categorization is based on standards relevant at the time of data collection.37      
*Viral suppression was defined as (<400 copies/ml3) at the time of study enrollment; the current definition is 







Table D.2. Sensitivity analysis identical to the primary analysis but allowing women to enroll throughout the second trimester of 
pregnancy. Analysis 1 assumes that randomization is unconditional (no model adjustment) and Analysis 2 assumes that 
randomization is conditional on baseline covariates. 





(%) RR 95% CI*   RR 95% CI    
Senstivity 1: Enrolling in 2nd 
Trimester N = 972               
PI cART 55 18.8 1.     1.     
No Therapy 109 22.2 1.18 (0.88, 1.58)    0.94 (0.66, 1.35)   
ZDV Monotherapy 29 19.9 1.06 (0.70, 1.58)   0.94 (0.62, 1.43)    
NNRTI cART 4 9.3 0.49 (0.19, 1.29)   0.49 (0.19, 1.25)   
**Model adjusted for the following minimally sufficient baseline covariates to emulate baseline randomization: baseline viral load, pre-
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